Page last updated: 2024-12-06

chloroquine diphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Chloroquine diphosphate is a synthetic antimalarial drug that has been used to treat malaria for over 60 years. It is also being investigated for its potential use in treating other diseases, such as rheumatoid arthritis, lupus, and certain types of cancer. Chloroquine is a weak base and exists in solution as a mixture of protonated and unprotonated forms. The protonated form is more soluble in water and is thought to be the active form of the drug. The diphosphate salt is used to increase the water solubility of chloroquine. Chloroquine is thought to work by accumulating in the acidic food vacuoles of malaria parasites. This accumulation inhibits the parasite's ability to digest hemoglobin, which is essential for the parasite's survival. Chloroquine is also thought to interfere with the parasite's DNA replication and protein synthesis. Chloroquine is generally well-tolerated, but it can cause side effects such as nausea, vomiting, diarrhea, headache, and dizziness. In rare cases, it can also cause more serious side effects, such as retinal damage and heart problems. Chloroquine is an important drug for the treatment of malaria, and it is being studied for its potential use in treating other diseases.'

Cross-References

ID SourceID
PubMed CID64927
CHEMBL ID58510
SCHEMBL ID40827
MeSH IDM0081184
PubMed CID639540
CHEMBL ID250447
CHEBI ID39254
SCHEMBL ID8934
MeSH IDM0081184
PubMed CID83818
CHEMBL ID1326
SCHEMBL ID40829
MeSH IDM0081184

Synonyms (197)

Synonym
AC-12463
alermine
quinoline, 7-chloro-4-(4-diethylamino-1-methyl-butylamino)-, diphosphate
h-stadur
quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, phosphate (1:2)
ccris 1554
tanakan (antimalarial)
chloroquine bis(phosphate)
ai3-14952
chingaminum
n(4)-(7-chloro-4-quinolinyl)-n(1),n(1)-diethyl-1,4-pentanediamine, phosphate (1:2)
1,4-pentanediamine, n(sup 4)-(7-chloro-4-quinolinyl)-n(sup 1),n(sup 1)-diethyl-, phosphate (1:2)
7-chlor-4-(4-(diaethylamino)-1-methylbutylamino)-chinolindiphosphat [german]
nsc 14050
chloroquine dihydrogen phosphate (1:2)
chlorochin diphosphate
wr 1522
dl-chloroquine diphosphate
1,4-pentanediamine, n4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-, phosphate (1:2)
einecs 200-055-2
7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline phosphate (1:2)
EU-0100296
chloroquine diphosphate salt, solid, >=98%
aralen diphosphate
chloroquin diphosphate
chingamin phosphate
chloroquine diphosphate
aralen phosphate
sn 7,618
resochin
avloclor
chloroquine phosphate
arechin
tanakan
nsc-14050
50-63-5
PRESTWICK_867
sn-7618
D02125
aralen (tn)
chloroquine phosphate (usp)
NCGC00093746-03
NCGC00093746-02
SPECTRUM1500179
NCGC00093746-01
C 6628
HMS2091C16
7-chloro-4-[4-(diethylamino)-1-methylbutylamino]quinoline diphosphate
C2301
n4-(7-chloro-4-quinolyl)-n1,n1-diethyl-1,4-pentanediamine diphosphate
CHEMBL58510
chloroquini phosphas
wr-1522
HMS501E06
HMS1569N17
HMS1920O05
AKOS004910410
HMS2096N17
HMS3260L14
7-chlor-4-(4-(diaethylamino)-1-methylbutylamino)-chinolindiphosphat
6e17k3343p ,
unii-6e17k3343p
unikinon
chloroquine phosphate [usp:ban]
1,4-pentanediamine, n4-(7-chloro-4-quinolinyl)-n',n'-diethyl-, (+-)-, phosphate (1:2)
NCGC00260384-01
tox21_202838
A828213
n4-(7-chloroquinolin-4-yl)-n1,n1-diethylpentane-1,4-diamine bis(phosphate)
n4-(7-chloro-4-quinolinyl)-n1,n1-dimethyl-1,4-pentanediamine diphosphate salt
tox21_110115
dtxsid7044681 ,
dtxcid5024681
S4157
CCG-39643
chloroquine diphosphate salt
FT-0602804
LP00296
chloroquine phosphate [usp-rs]
chloroquine phosphate [who-dd]
chloroquine phosphate [usp monograph]
chloroquine phosphate [who-ip]
7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline phosphate (1:2).
chloroquini phosphas [who-ip latin]
chloroquine phosphate [green book]
chloroquine phosphate [vandf]
chloroquine phosphate [mart.]
chloroquine phosphate [ep monograph]
chloroquine diphosphate [mi]
chloroquine phosphate [orange book]
SCHEMBL40827
NCGC00015256-12
tox21_110115_1
n4-(7-chloro-4-quinolyl)-n1,n1-diethyl-pentane-1,4-diamine; phosphoric acid
NCGC00260981-01
tox21_500296
CS-3811
F2173-1139
chloroquine (phosphate)
HY-17589
chloroquinediphosphate
mfcd00069852
SR-01000075548-1
sr-01000075548
chloroquine phosphate, united states pharmacopeia (usp) reference standard
chloroquine phosphate, pharmaceutical secondary standard; certified reference material
chloroquindiphosphat
SR-01000075548-3
SR-01000075548-5
HMS3713N17
Z1541662176
BCP31956
chloroquine phosphate;aralen phosphate;7-chloro-4-((4 inverted exclamation mark -diethylamino-1-methylbutyl)amino)quinolinediphosphate
DT-0015
n4-(7-chloroquinolin-4-yl)-n1,n1-diethylpentane-
1,4-diamine bis(phosphate)
chloroquine diphosphate,(s)
7-chloro-4-[4-(diethylamino)-1-methylbutylamino]quinoline bis(phosphate)
SY021941
D70732
Q27264629
50-63-5 (diphosphate)
EN300-100253
7-chloro-n-[5-(diethylamino)pentan-2-yl]quinolin-4-amine; bis(phosphoric acid)
HB5073
c18h26cln3?2h3po4
chloroquine (phosphate) (standard)
CS-0695021
HY-17589R
chloroquine phosphate (usp monograph)
chloroquine phosphate (usp-rs)
chloroquinum phos.
chloroquine phosphate (mart.)
chloroquine phosphate (ep monograph)
chloroquine phosphate (usp:ban)
BIDD:PXR0167
1,4-pentanediamine, n4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-, (+)-
(+)-n4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-1,4-pentanediamine
chloroquine, d-
chloroquine, (s)-
34p96m7c4k ,
unii-34p96m7c4k
0tx ,
(4s)-n~4~-(7-chloroquinolin-4-yl)-n~1~,n~1~-diethylpentane-1,4-diamine
cas-50-63-5
lopac-c-6628
NCGC00015256-01
NCGC00016223-01
(4s)-n(4)-(7-chloroquinolin-4-yl)-n(1),n(1)-diethylpentane-1,4-diamine
(s)-chloroquine
CHEBI:39254 ,
(+)-chloroquine
58175-86-3
(+)-n(4)-(7-chloro-4-quinolinyl)-n(1),n(1)-diethyl-1,4-pentanediamine
CHEMBL250447
SCHEMBL8934
1,4-pentanediamine, n4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-, (4s)-
Q27119790
(s)-n4-(7-chloroquinolin-4-yl)-n1,n1-diethylpentane-1,4-diamine
DTXSID401316967
(s)-(+)-chloroquine
E80613
PD070331
1,4-pentanediamine, n4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-, phosphate (1:1)-
chloroquinine phosphate
chloroquine, phosphate
quinoline, 7-chloro-4-((4-(diethylamino)-1-methylbutyl)amino)-, phosphate (1:1)
resochin diphosphate
1, n4-(7-chloro-4-quinolinyl)-n1,n1-diethyl-, phosphate (1:2)
wln: t66 bnj emy1&3n2&2 ig &p2-o6
7-chloro-4-[(4'-diethylamino-1-methylbutyl)amino]quinoline diphosphate
quinoline, diphosphate
NCGC00180905-01
NCGC00180905-02
araten phosphate
egb761
TCMDC-123988 ,
CHEMBL1326
1446-17-9
7fy24he2g3 ,
chloroquine monophosphate
unii-7fy24he2g3
pharmakon1600-01500179
nsc756681
nsc-756681
chloroquine monophosphate [who-dd]
AKOS025310652
SCHEMBL40829
4-n-(7-chloroquinolin-4-yl)-1-n,1-n-diethylpentane-1,4-diamine;phosphoric acid
phosphoric acid--n~4~-(7-chloroquinolin-4-yl)-n~1~,n~1~-diethylpentane-1,4-diamine (1/1)
DTXSID10932343
quinoline, 7-chloro-4-[(4-diethylamino-1-methylbutyl)amino]-, diphosphate (6ci)
Q27268205
7-chloro-n-[5-(diethylamino)pentan-2-yl]quinolin-4-amine; phosphoric acid
EN300-19807744
chloroquinephosphate
PD052310

Research Excerpts

Overview

Chloroquine diphosphate (CDP) is a helpful tool in the blood bank for two main applications.

ExcerptReferenceRelevance
"Chloroquine diphosphate (CDP) is a helpful tool in the blood bank for two main applications. "( Utility of chloroquine diphosphate in the blood bank laboratory.
Arndt, PA; Aye, T, 2018
)
2.31

Toxicity

ExcerptReferenceRelevance
" In conclusion, child in utero exposure to chloroquine diphosphate does not seem to induce hearing impairment as measured by pure tone audiometry, reinforcing its safe use during pregnancy of lupus patients."( Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry.
Bertola, C; Bonfá, E; Borba, EF; Kuruma, KA; Lorenzi, MC; Pedalini, ME; Turrini-Filho, JR, 2004
)
0.59
" Results obtained indicated adverse effects of CQ in a dose-dependent manner."( Role of curcumin on chloroquine phosphate-induced reproductive toxicity.
Dattani, JJ; Desai, KR; George, LB; Highland, HN; Moid, N; Rajput, DK, 2012
)
0.38
" The commonly reported clinical adverse event was vomiting."( Efficacy and safety of fixed dose combination of arterolane maleate and piperaquine phosphate in comparison with chloroquine phosphate in children with acute uncomplicated
Anvikar, AR; Bahl, RK; Baliga, BS; Bhardwaj, AC; Choudhury, R; Das, RR; Ghosh, SK; Goyal, VK; Jalali, RK; Jauhri, N; Khurana, O; Mishra, DN; Nasa, A; Pandey, M; Punj, A; Roy, A; Sharma, SK; Soans, ST; Srivastava, B; Valecha, N,
)
0.13
"The safety assessment revealed no adverse effect of the drugs in COVID-19 patients after treatment."( Preliminary Study on Open Labelled Randomized Controlled Trial of the Safety and Efficacy of Hydroxychloroquine and Chloroquine Phosphate for the Treatment of Persons Infected with 2019 Coronavirus Disease in Nigeria.
Abiola, A; Adeyemo, WL; Agabi, OP; Aina, OO; Ajibaye, O; Akase, IE; Akinbode, GO; Akintan, PE; Amoo, OS; Audu, RA; Bamidele, TA; Bode, C; Busari, AA; David, AN; Esezobor, C; Ezechi, OC; Fadipe, B; Ima-Edomwonyi, E; James, AB; Musa, AZ; Nmadu, N; Okoyenta, CO; Okwuraiwe, AP; Oladele, DA; Olakiigbe, AK; Olopade, OB; Osuolale, KA; Otrofanowei, E; Raheem, TY; Salako, AO; Salako, BL; Tade, T, 2023
)
0.91
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters calculated using model-independent methods showed good agreement with model-dependent methods."( Pharmacokinetics of chloroquine diphosphate in the dog.
Aderounmu, AF; Fleckenstein, L, 1983
)
0.59

Compound-Compound Interactions

ExcerptReferenceRelevance
" The author here is proposing to test 5-FU in combination with a number of deoxynucleosides on animal models infected with this Covid-19."( 5-Fluorouracil in combination with deoxyribonucleosides and deoxyribose as possible therapeutic options for the Coronavirus, COVID-19 infection.
Ahmad, SI, 2020
)
0.56

Bioavailability

ExcerptReferenceRelevance
"It is now recognized that intestinal metabolism is one of the major factors affecting the bioavailability of orally administered, natural and synthetic estrogens."( Drug effects on the intestinal absorption of estrogens.
Dada, OA; Martins, OO, 1983
)
0.27
" With the aim of excluding treatment failures due to low bioavailability, we have investigated the absolute bioavailability of MB given as an aqueous oral formulation and its interaction with chloroquine (CQ)."( High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Burhenne, J; Meissner, P; Mikus, G; Mueller, O; Oberwittler, H; Rengelshausen, J; Walter-Sack, I, 2009
)
0.35
" The absolute bioavailability was 72."( High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Burhenne, J; Meissner, P; Mikus, G; Mueller, O; Oberwittler, H; Rengelshausen, J; Walter-Sack, I, 2009
)
0.35
"The absolute bioavailability of MB is high."( High absolute bioavailability of methylene blue given as an aqueous oral formulation.
Burhenne, J; Meissner, P; Mikus, G; Mueller, O; Oberwittler, H; Rengelshausen, J; Walter-Sack, I, 2009
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."( Hologram QSAR model for the prediction of human oral bioavailability.
Andricopulo, AD; Moda, TL; Montanari, CA, 2007
)
0.34
"The knowledge on human serum albumin (HSA) binding is of utmost importance as it affects pharmacokinetic behavior and bioavailability of drugs."( Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
Bajusz, D; Balogh, GT; Dargó, G; Müller, J; Simon, K, 2020
)
0.56

Dosage Studied

Male Wistar rats were intraperitoneally injected with chloroquine diphosphate at a dosage of 50 mg/kg body weight every day. The standard reference drug which had a % suppression of 90.

ExcerptRelevanceReference
" A stepwise multiple regression analysis was used to evaluate the dose-response relationship between the registered data on one hand and solvent exposure, employment on chemical tankers, age, alcohol and chloroquine phosphate consumption on the other."( Seamen exposed to organic solvents. A cross-sectional study with special reference to the nervous system.
Fossan, GO; Moen, BE; Riise, T; Todnem, K, 1988
)
0.27
" Based on these observations and the fact that authors who have observed an inhibition of the collagen synthesis have used an uncomparibly higher dosage per kilogram of body weight, the authors of this report are so far of the opinion that the dosage they are using (300-600 mg/day) does not significantly influence the speed of wound healing."( [D-penicillamine and wound healing in patients with rheumatoid arthritis].
Bamert, W; Stojan, B; Wiedmer, U,
)
0.13
" For patients using chloroquine, the correlation between RNFL measurements and chloroquine dosage was assessed."( Retinal nerve fibre layer thickness measurements in patients using chloroquine.
Bonanomi, MT; Dantas, NC; Medeiros, FA, 2006
)
0.33
" Multiple chloroquine drug doses were used, revealing the existence of inverted-U dose-response relationships in every strain, allowing us to determine strain-dependent peak scratching behavior over the entire dose range."( Influence of genotype, dose and sex on pruritogen-induced scratching behavior in the mouse.
Green, AD; Lehto, SG; Mogil, JS; Smith, SB; Young, KK, 2006
)
0.33
" Male Wistar rats were intraperitoneally injected with chloroquine diphosphate at a dosage of 50 mg/kg body weight every day."( Amyloid-beta accumulation caused by chloroquine injections precedes ER stress and autophagosome formation in rat skeletal muscle.
Arahata, H; Fujii, N; Furuya, H; Ikezoe, K; Kira, J; Nakagawa, M; Tateishi, T, 2009
)
0.6
" Within 1 month after initiating dapsone therapy and increasing the dosage of prednisone, skin lesions promptly resolved."( Detection of Type VII Collagen Autoantibodies Before the Onset of Bullous Systemic Lupus Erythematosus.
Chong, BF; Grabell, DA; Matthews, LA; Yancey, KB, 2015
)
0.42
"66) at the highest dosage administered (800 mg/kg) when compared with chloroquine diphosphate, the standard reference drug which had a % suppression of 90."( Antimalarial and cytotoxic properties of Chukrasia tabularis A. Juss and Turraea vogelii Hook F. Ex. Benth.
Ajaiyeoba, EO; Fadare, AA; Fasinu, PS; Ogbole, OO; Saka, YA, 2016
)
0.67
" Lipid based nanodrug delivery systems have been very popular in the recent times as they are very less toxic, have drug targeting capabilities and also reduces the dosing frequency by increasing efficacy of the drug."( Optimisation of chloroquine phosphate loaded nanostructured lipid carriers using Box-Behnken design and its antimalarial efficacy.
Baruah, UK; Gowthamarajan, K; Karri, VVSR; Ravisankar, V; Simhadri, PK; Singh, V, 2018
)
0.48
"The preliminary findings of this study suggest that the higher CQ dosage should not be recommended for critically ill patients with COVID-19 because of its potential safety hazards, especially when taken concurrently with azithromycin and oseltamivir."( Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
Albuquerque, BC; Alexandre, MAA; Baía-da-Silva, D; Balieiro, AAS; Bassat, Q; Borba, MGS; Brito, M; Brito-Sousa, JD; Croda, J; Daniel-Ribeiro, CT; Fontes, CJ; Guerra, MVF; Hajjar, LA; Lacerda, MVG; Melo, GC; Monteiro, WM; Mourão, MPG; Naveca, FG; Nogueira, ML; Pacheco, AGF; Pinto, RC; Romero, GAS; Sampaio, VS; Santos, JDO; Schwarzbold, A; Siqueira, AM; Val, FFA; Xavier, MS, 2020
)
0.84
" Understanding the pharmacokinetics (PK) in COVID-19 patients is essential to study its exposure-efficacy/safety relationship and provide a basis for a possible dosing regimen optimization."( Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.
Cai, T; Cui, C; Hou, Z; Li, H; Lin, J; Liu, D; Liu, Q; Wang, X; Xiong, Z; Yan, X; Yao, X; Zhang, S, 2021
)
0.62
"Model-based simulation using PK parameters from the COVID-19 patients shows that the concentrations under the currently recommended dosing regimen are below the safety margin for side-effects, which suggests that these dosing regimens are generally safe."( Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients.
Cai, T; Cui, C; Hou, Z; Li, H; Lin, J; Liu, D; Liu, Q; Wang, X; Xiong, Z; Yan, X; Yao, X; Zhang, S, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
chloroquineAn aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency44.66840.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
endonuclease IVEscherichia coliPotency11.22020.707912.432431.6228AID1708
acetylcholinesteraseHomo sapiens (human)Potency7.21800.002541.796015,848.9004AID1347395; AID1347397; AID1347398
GALC proteinHomo sapiens (human)Potency3.162328.183828.183828.1838AID1159614
TDP1 proteinHomo sapiens (human)Potency24.60140.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency5.80240.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency7.94330.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency1.12290.000221.22318,912.5098AID1259243; AID1259381
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency8.81160.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency0.11880.000417.946075.1148AID1346784
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency31.62280.01237.983543.2770AID1346984
retinoid X nuclear receptor alphaHomo sapiens (human)Potency0.84850.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency1.67850.001530.607315,848.9004AID1224841
estrogen nuclear receptor alphaHomo sapiens (human)Potency4.37400.000229.305416,493.5996AID1259244; AID743075; AID743080
cytochrome P450 2D6Homo sapiens (human)Potency15.09160.00108.379861.1304AID1645840
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency6.56790.023723.228263.5986AID743223
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency21.71230.01789.637444.6684AID588834
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.39140.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency12.99160.000627.21521,122.0200AID743202
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.94390.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.94390.001551.739315,848.9004AID1259244
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency0.01000.004023.8416100.0000AID485290
USP1 protein, partialHomo sapiens (human)Potency39.81070.031637.5844354.8130AID504865
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency39.81070.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency15.84890.00255.840031.6228AID899
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency6.47760.00106.000935.4813AID943; AID944
lethal factor (plasmid)Bacillus anthracis str. A2012Potency19.95260.020010.786931.6228AID912
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Histidine-rich protein PFHRP-IIPlasmodium falciparum (malaria parasite P. falciparum)IC50 (µMol)5,900.00000.07651.12552.9000AID320724
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (396)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID402115Antimalarial activity against Plasmodium falciparum K1 by [3H]hypoxanthine uptake1998Journal of natural products, Sep, Volume: 61, Issue:9
Antimalarial principles from Artemisia indica.
AID123377In vivo activity against Plasmodium berghei parasitaemia1997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6.
AID158854In vitro inhibitory activity against Plasmodium falciparum FCB21996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes.
AID337702Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 infected human erythrocytes assessed by [3H]hypoxanthine uptake
AID1472099Selectivity index, ratio of IC50 for CHO cells to IC50 for chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF542017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID158044In vitro growth inhibition as IC50 against chloroquine-resistant Plasmodium falciparum FcB21997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6.
AID377563Cytotoxicity against human KB cells after 48 hrs by MTT assay2000Journal of natural products, Sep, Volume: 63, Issue:9
Activity of extracts and isolated naphthoquinones from Kigelia pinnata against Plasmodium falciparum.
AID1057138Ratio of IC50 for drug-resistant Plasmodium falciparum C235 to IC50 for drug-sensitive Plasmodium falciparum D62013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID285331Growth inhibition after 72 hrs of Plasmodium falciparum 3D7 by SYBR green assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID385159Antiplasmodial activity against Plasmodium falciparum 3D72008Journal of natural products, Apr, Volume: 71, Issue:4
Combining HPLC-PDA-MS-SPE-NMR with circular dichroism for complete natural product characterization in crude extracts: levorotatory gossypol in Thespesia danis.
AID445065Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum MRC-02 infected in human erythrocyte assessed as inhibition of schizont maturation after 24 hrs2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID389363Inhibition of beta-hematin formation assessed as drug: hematin molar ratio causing inhibition of hem polymerization after 24 hrs by HPIA method2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity.
AID285333Growth inhibition after 72 hrs of Plasmodium falciparum D6 by SYBR green I assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID759716Antimalarial activity against multidrug-resistant Plasmodium falciparum TM90C2B after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID442673Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay in presence of 0.4 uM 1-(1-(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID343462Antimalarial activity as survival time in Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 30 mg/kg subcutaneous dose after 3 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID765572Antimalarial activity against Plasmodium falciparum NF54 infected in human serum after 48 hrs by fluorometric method2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis of novel analogs of 2-pyrazoline obtained from [(7-chloroquinolin-4-yl)amino]chalcones and hydrazine as potential antitumor and antimalarial agents.
AID765573Antimalarial activity against Plasmodium falciparum NF54 infected in human serum at 22.2 ug/ml after 48 hrs by fluorometric method2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis of novel analogs of 2-pyrazoline obtained from [(7-chloroquinolin-4-yl)amino]chalcones and hydrazine as potential antitumor and antimalarial agents.
AID445068Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum RKL09 infected in human erythrocyte assessed as inhibition of schizont maturation after 24 hrs2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID1460818Antiparasitic activity against chloroquine-resistant Plasmodium falciparum FcB1/Columbia infected in human erythrocytes assessed as reduction in [3H]-hypoxanthine incorporation incubated for 24 hrs assay by liquid scintillation spectrometry2017Journal of natural products, 04-28, Volume: 80, Issue:4
Revisiting Previously Investigated Plants: A Molecular Networking-Based Study of Geissospermum laeve.
AID494641Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte after 48 h by SYBR-Green-1 assay2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Synthesis of novel alpha-pyranochalcones and pyrazoline derivatives as Plasmodium falciparum growth inhibitors.
AID252933Relative IC50 ratio against Plasmodium falciparum K1 compared to chloroquine diphosphate2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID1059802Kinetic solubility of the compound in phosphate buffered saline at pH 7.4 after 2 hrs by HPLC analysis2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds.
AID1275423Antiplasmodial activity against chloroquine resistant Plasmodium falciparum K1 infected in human erythrocytes incubated for 72 hrs by SYBR Green1-based fluorescence analysis2016European journal of medicinal chemistry, Feb-15, Volume: 109Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
AID1534798Anti-plasmodial activity against chloroquine resistant Plasmodium falciparum RKL9 infected in human erythrocytes after 24 hrs by Giemsa staining-based method2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis, in silico experiments and biological evaluation of 1,3,4-trisubstituted pyrazole derivatives as antimalarial agents.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID152003In vitro inhibitory activity against chloroquine-resistant Plasmodium falciparum K12001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents.
AID459110Therapeutic index, Cytotoxicity against human KB cells to Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K12010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID1472096Antiplasmodial activity against chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum 7G8 after 48 hrs by NBT dye based LDH assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID253006Mean survival time taken as number of days before illness due to Plasmodium berghei in untreated mice (Mus musculus)2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID445076Antimalarial activity against Plasmodium berghei ANKA infected in Swiss albino mice (Mus musculus) assessed as mean survival time at 8 mg/kg/day, perorally for 4 days measured after 28 days2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID343463Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 30 mg/kg/day peroral dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID384960Antimalarial activity against Plasmodium falciparum 3D7A infected erythrocytes by [3H]hypoxanthine uptake2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
AID442680Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay in presence of 0.5 uM 2-morpholino-8-phenyl-4H-chromen-4-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID759717Antimalarial activity against multidrug-resistant Plasmodium falciparum TM90C2A after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID157669In vitro antimalarial activity against multidrug-resistant Plasmodium falciparum K12003Journal of medicinal chemistry, Jun-05, Volume: 46, Issue:12
Synthesis of ethyl 5-phenyl-6-oxa-1-azabicyclo[3.1.0]hexane-2-carboxylate derivatives and evaluation of their antimalarial activities.
AID241713In vitro antiplasmodial concentration against multidrug-resistant Plasmodium falciparum K12005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID490213Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum MRC2 infected in human erythrocytes after 24 hrs by Giemsa staining2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
In vitro and in vivo antimalarial evaluation of semi-synthetic derivatives of gomphostenin.
AID248025In vitro inhibition of Plasmodium falciparum K12004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID1638526Antimalarial activity against artemisinin-resistant Plasmodium falciparum MRA1240 pretreated for 24 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by [3H]-hypoxanthine growth inhibition assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1152804Antiplasmodial activity against drug susceptible Plasmodium falciparum 3D7 NF54 isolate in human erythrocytes assessed as growth inhibition after 48 hrs by optical microscopy2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID343456Cytotoxicity against mouse WEHI clone 13 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID357917Cytotoxicity against human HeLa cells after 24 hrs by [3H]hypoxanthine incorporation assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID459107Antiplasmodial activity in chloroquine-nonsensitive Plasmodium yoelii infected BALB/c mice (Mus musculus) assessed as inhibition of parasitaemia at 1 mg/kg, intraperitoneally daily once for 4 days2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID759719Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D6 after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID442686Cytotoxicity against human 184B5 cells after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID1732344Binding affinity to Fe(III)PPIX (unknown origin) assessed as association constant by UV-Vis spectrophotometric analysis relative to control2021European journal of medicinal chemistry, Apr-05, Volume: 215In vitro and in vivo antiplasmodial activity of novel quinoline derivative compounds by molecular hybridization.
AID343467Antimalarial activity as survival time against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 10 mg/kg/day peroral dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID248061In vitro inhibition of Plasmodium falciparum FcB12004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID360829Antimalarial activity as reduced parasitaemia at day 5 against Plasmodium berghei ANKA infected in BALB/c mice (Mus musculus) at 10 mg/kg/day intraperitoneal dose over 4 days2002Journal of natural products, Jul, Volume: 65, Issue:7
Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicine.
AID1237966Antitrypanosomal activity against Trypanosoma brucei brucei CMP infected in Swiss mouse assessed as mean survival time at 100 umol/kg, ip administered as single dose2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
New heterocyclic compounds: Synthesis and antitrypanosomal properties.
AID378593Cytotoxicity against human KB cells after 72 hrs2000Journal of natural products, Dec, Volume: 63, Issue:12
In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids.
AID360827Ratio of IC50 for chloroquine-resistant Plasmodium falciparum K1 to IC50 for chloroquine-sensitive Plasmodium falciparum HB32002Journal of natural products, Jul, Volume: 65, Issue:7
Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicine.
AID384961Antimalarial activity against Plasmodium falciparum FCR3-A infected erythrocytes as [3H]hypoxanthine incorporation2008Journal of medicinal chemistry, May-08, Volume: 51, Issue:9
Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials.
AID502658Inhibition of beta-hematin formation after 18 hrs by microtiter plate assay2010Bioorganic & medicinal chemistry, Sep-15, Volume: 18, Issue:18
Structure-activity relationships of mononuclear metal-thiosemicarbazone complexes endowed with potent antiplasmodial and antiamoebic activities.
AID285332Growth inhibition after 72 hrs of Plasmodium falciparum 3D7 by HRPII ELISA2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID285334Growth inhibition after 72 hrs of Plasmodium falciparum D6 by HRPII ELISA2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID1140750Inhibition of Clostridium botulinum recombinant BoNT/A light chain using N-terminal acetylated, C-terminal aminated SNAP-25 (187-203) as substrate at 20 uM by reverse-phase HPLC analysis2014Journal of medicinal chemistry, May-22, Volume: 57, Issue:10
Second generation steroidal 4-aminoquinolines are potent, dual-target inhibitors of the botulinum neurotoxin serotype A metalloprotease and P. falciparum malaria.
AID490218Antimalarial activity against chloroquine-sensitive Plasmodium berghei ANKA infected in Swiss mice (Mus musculus) assessed as parasitaemia at 5 mg/kg, perorally for 4 days measured on day 52010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
In vitro and in vivo antimalarial evaluation of semi-synthetic derivatives of gomphostenin.
AID1237974Antitrypanosomal activity against Trypanosoma brucei brucei CMP infected in Swiss mouse assessed as parasite number level ul of blood at 100 umol/kg, ip administered as single dose measured on day 42015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
New heterocyclic compounds: Synthesis and antitrypanosomal properties.
AID418854Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D72009Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7
Synthesis, antimalarial activity, and preclinical pharmacology of a novel series of 4'-fluoro and 4'-chloro analogues of amodiaquine. Identification of a suitable "back-up" compound for N-tert-butyl isoquine.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID420491Antimalarial activity against Plasmodium falciparum K12009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
New antimalarial and cytotoxic 4-nerolidylcatechol derivatives.
AID443015Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 (Thailand) assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID158853In vitro inhibitory activity against Plasmodium falciparum FcB11996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes.
AID1275410Resistance index, ratio of IC50 for chloroquine resistant Plasmodium falciparum K1 infected in human erythrocytes to IC50 for chloroquine sensitive Plasmodium falciparum 3D7 infected in human erythrocytes2016European journal of medicinal chemistry, Feb-15, Volume: 109Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
AID252936Selectivity for chloroquine diphosphate over Plasmodium falciparum FcB1 as IC50 ratio2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID442671Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID1067836Binding affinity to monomeric Fe(III)PPIX at pH 5.62014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID459106Antiplasmodial activity in chloroquine-nonsensitive Plasmodium yoelii infected BALB/c mice (Mus musculus) assessed as inhibition of parasitaemia at 3 mg/kg, intraperitoneally daily once for 4 days2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID1349120Antiproliferative activity against human MCF7 cells after 48 hrs by SRB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.
AID759718Antimalarial activity against multi drug resistant Plasmodium falciparum TM91C235 after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID356617Cytotoxicity against human KB cells by microplate method2003Journal of natural products, Nov, Volume: 66, Issue:11
Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone.
AID1275409Selectivity index, ratio of CC50 for monkey kidney VERO cells to IC50 for chloroquine resistant Plasmodium falciparum K1 infected in human erythrocytes2016European journal of medicinal chemistry, Feb-15, Volume: 109Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
AID1152806Cytotoxicity against mouse macrophages after 18 hrs by MTT assay2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID442689Cytotoxicity against human 184B5 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID490214Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum RKL9 after 24 hrs by Giemsa staining2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
In vitro and in vivo antimalarial evaluation of semi-synthetic derivatives of gomphostenin.
AID1534797Anti-plasmodial activity against Plasmodium berghei ANKA infected in mouse assessed as mean survival time at 0.048 mmol/kg/day, po administered as single dose at 24 hrs time interval from day 1 to day 3 and measured 96 hrs post infection (Rvb = 4.33 +/- 02019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis, in silico experiments and biological evaluation of 1,3,4-trisubstituted pyrazole derivatives as antimalarial agents.
AID377561Antimalarial activity after 48 hrs against chloroquine-sensitive Plasmodium falciparum T9-96 by LDH reporter assay2000Journal of natural products, Sep, Volume: 63, Issue:9
Activity of extracts and isolated naphthoquinones from Kigelia pinnata against Plasmodium falciparum.
AID459108Antiplasmodial activity in chloroquine-nonsensitive Plasmodium yoelii infected intraperitoneally dosed BALB/c mice (Mus musculus) assessed as inhibition of parasitaemia administered daily once for 4 days2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID248766Normalized IC50 as product of antiplasmodial IC50 and vacuolar accumulation IC502005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID1067832Binding affinity to mu-oxodimeric heme at pH 5.82014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID443013Therapeutic index, ratio of IC50 for human KB cells to IC50 for Plasmodium falciparum 3D72010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID1067828Binding affinity to calf thymus DNA by fluorescence spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID378591Antiplasmodial activity against multi drug-resistant Plasmodium falciparum K1 in erythrocytes by [3H]hypoxanthine uptake2000Journal of natural products, Dec, Volume: 63, Issue:12
In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids.
AID443011Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as growth inhibition by [3H]hypoxanthine incorporation assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID248041In vitro inhibition of Plasmodium falciparum F322004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID357913Antiplasmodial activity after 24 hrs against chloroquine-sensitive Plasmodium falciparum Nigerian by [3H]hypoxanthine uptake2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID343455Inhibition of beta-hematin formation as ratio to heme molar equivalent in Plasmodium falciparum2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID1430060Selectivity index, ratio of CC50 for monkey Vero C1008 cells to IC50 for chloroquine-sensitive Plasmodium falciparum 3D7
AID494644Cytotoxicity against human HeLa cells after 24 to 48 hrs by MTT assay2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Synthesis of novel alpha-pyranochalcones and pyrazoline derivatives as Plasmodium falciparum growth inhibitors.
AID1077197Resistance index, ratio of IC50 for asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 to IC50 for asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF542014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1274028Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 48 hrs by alamar blue assay2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and antimalarial activity of quinones and structurally-related oxirane derivatives.
AID285335Growth inhibition after 72 hrs of Plasmodium falciparum W2 by SYBR green I assay2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID1472107Inhibition of beta hematin formation by detergent based assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID285336Growth inhibition after 72 hrs of Plasmodium falciparum W2 by HRPII ELISA2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates.
AID459102Antiplasmodial activity in chloroquine-sensitive Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) assessed as inhibition of parasitemia at 10 mg/kg, intraperitoneally daily once for 4 days2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID1348804Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infecetd in RBC after 72 hrs by SYBR Green dye-based fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Substituted carbamothioic amine-1-carbothioic thioanhydrides as novel trichomonicidal fungicides: Design, synthesis, and biology.
AID1067857Solubility of the compound in octanol at pH 7.4 by HPLC analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID1237970Toxicity against Swiss mouse infected with Trypanosoma brucei brucei CMP assessed as animal death at 100 umol/kg, ip administered as single dose2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
New heterocyclic compounds: Synthesis and antitrypanosomal properties.
AID1150088Binding affinity to sonicated Escherichia coli ColE1 DNA by viscometric titrations1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID442675Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay in presence of 0.5 uM 2-morpholino-8-phenyl-4H-chromen-4-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID442688Cytotoxicity against human 184B5 cells after 48 hrs by SRB assay in presence of 0.4 uM 1-(1-(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID442677Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay in presence of 0.04 uM (E)-5-(benzo[d]thiazol-2-yl)-3-ethyl-2-(2-(methyl(phenyl)amino)vinyl)-1-phenyl-1H-benzo[d]imidazol-3-ium iodide2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID759720Inhibition of Clostridium botulinum recombinant BoNT/A light chain at 20 mM by reverse-phase HPLC analysis2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID343770Inhibition of CYP2D6 at 3 uM2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID357914Antiplasmodial activity after 72 hrs against chloroquine-sensitive Plasmodium falciparum Nigerian by [3H]hypoxanthine uptake2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID357918Cytotoxicity against human HeLa cells after 72 hrs by [3H]hypoxanthine incorporation assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID1274027Antimalarial activity against chloroquine-sensitive NF54 isolated Plasmodium falciparum 3D7 infected in erythrocytes assessed as inhibition of parasitic growth after 48 hrs by optical microscopy2016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and antimalarial activity of quinones and structurally-related oxirane derivatives.
AID1059801Kinetic solubility of the compound in 0.01 M HCl at pH 2 after 2 hrs by HPLC analysis2013ACS medicinal chemistry letters, Dec-12, Volume: 4, Issue:12
Synthesis and in vitro and in vivo pharmacological evaluation of new 4-aminoquinoline-based compounds.
AID442679Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID443014Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as growth inhibition by [3H]hypoxanthine incorporation assay relative to artemisinin2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID245851Ionization constant for the compound2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID343470Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 3 mg/kg/day subcutaneous dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID248026In vitro inhibition of Plasmodium falciparum W22004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID1237973Antitrypanosomal activity against Trypanosoma brucei brucei CMP infected in Swiss mouse assessed as parasite number level ul of blood at 100 umol/kg, ip administered as single dose measured on day 32015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
New heterocyclic compounds: Synthesis and antitrypanosomal properties.
AID343451Antimalarial activity against chloroquine-sensitive Plasmodium falciparum D10 by LDH assay2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID529905Antiplasmodial activity against Plasmodium falciparum harboring K1 allele group of msp1, 3D7 allele group of msp2 gene and 94 bp of 7A11, 196bp of C4M79 and 336bp of C4M69 locus measured on day 23 by [3H]hypoxanthine incorporation assay2008Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6
First case of emergence of atovaquone-proguanil resistance in Plasmodium falciparum during treatment in a traveler in Comoros.
AID378592Antiamnesic activity against Entamoeba histolytica NIH 200 after 72 hrs by microdilution technique2000Journal of natural products, Dec, Volume: 63, Issue:12
In vitro antiplasmodial, antiamoebic, and cytotoxic activities of some monomeric isoquinoline alkaloids.
AID1275422Antiplasmodial activity against chloroquine sensitive Plasmodium falciparum 3D7 infected in human erythrocytes incubated for 72 hrs by SYBR Green1-based fluorescence analysis2016European journal of medicinal chemistry, Feb-15, Volume: 109Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
AID445066Cytotoxicity against human HeLa cells after 72 hrs by neutral red uptake assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID1274029Selectivity index, ratio of IC50 for MRC5 cells to IC50 for chloroquine-sensitive NF54 isolated Plasmodium falciparum 3D72016European journal of medicinal chemistry, Jan-27, Volume: 108Synthesis and antimalarial activity of quinones and structurally-related oxirane derivatives.
AID343468Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 10 mg/kg/day subcutaneous dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID1349121Antiproliferative activity against human 184B5 cells after 48 hrs by SRB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.
AID442685Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay in presence of 0.5 uM 2-morpholino-8-phenyl-4H-chromen-4-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID442678Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay in presence of 0.4 uM 1-(1-(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID759721Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 after 72 hrs by MSF assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID1067859Aqueous solubility of the compound in PBS buffer at pH 7.4 after 24 hrs by HPLC analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID1348805Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 infecetd in RBC after 72 hrs by SYBR Green dye-based fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Substituted carbamothioic amine-1-carbothioic thioanhydrides as novel trichomonicidal fungicides: Design, synthesis, and biology.
AID1057136Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID363636Cytotoxicity against human MCF7 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID1194357Antimalarial activity against multidrug-resistant Plasmodium falciparum thailand TM91C235 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID1638535Antimalarial activity against artemisinin-sensitive Plasmodium falciparum MRA1239 pretreated for 24 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by [3H]-hypoxanthine growth inhibition assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID1472088Resistance index, ratio of IC50 for chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum Dd2 to IC50 for chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF542017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID1193933Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human erythrocyte assessed as parasite viability after 48 hrs by [3H]hypoxanthine incorporation based liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, Apr-15, Volume: 23, Issue:8
Design, synthesis and biological evaluation of functionalized phthalimides: a new class of antimalarials and inhibitors of falcipain-2, a major hemoglobinase of malaria parasite.
AID459105Antiplasmodial activity in chloroquine-nonsensitive Plasmodium yoelii infected BALB/c mice (Mus musculus) assessed as inhibition of parasitaemia at 10 mg/kg, intraperitoneally daily once for 4 days2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID1057140Antimalarial activity against drug-sensitive Plasmodium falciparum D6 after 72 hrs by SYBR green I staining-based fluorescence assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1067835Binding affinity to monomeric Fe(III)PPIX at pH 7.42014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID1638533Antimalarial activity against Plasmodium falciparum D6 pretreated for 24 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by [3H]-hypoxanthine growth inhibition assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID377564Selectivity ratio of ED50 for KB cells to IC50 for Plasmodium falciparum K12000Journal of natural products, Sep, Volume: 63, Issue:9
Activity of extracts and isolated naphthoquinones from Kigelia pinnata against Plasmodium falciparum.
AID253254Vascular accumulation into acidic parasitic food vacuole at pH=5.52005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID343454Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 by [3H]hypoxanthine uptake2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID110857Inhibitory activity against Plasmodium berghei (ANKA) in mice at a dose of 10 mg/kg for 4 days2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents.
AID443012Cytotoxicity against human KB cells after 72 hrs by alamar blue assay2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID1150090Binding affinity to sonicated calf thymus DNA by viscometric titrations1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID158045In vitro inhibition as IC50 against Plasmodium falciparum by [3H]hypoxanthine uptake2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
New anti-malarial compounds from database searching.
AID1349118Antiproliferative activity against human MDA-MB-468 cells after 48 hrs by SRB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.
AID158814In vitro inhibitory activity against Plasmodium berghei1996Journal of medicinal chemistry, Mar-01, Volume: 39, Issue:5
Toward a novel metal-based chemotherapy against tropical diseases. 2. Synthesis and antimalarial activity in vitro and in vivo of new ruthenium- and rhodium-chloroquine complexes.
AID494642Antimalarial activity against chloroquine-resistant Plasmodium falciparum RKL9 infected in human erythrocyte after 48 h by SYBR-Green-1 assay2010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Synthesis of novel alpha-pyranochalcones and pyrazoline derivatives as Plasmodium falciparum growth inhibitors.
AID249556Antiplasmodial activity as IC50 against Beta-hematin formation2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID1194372Binding affinity to heme assessed as inhibition of beta-hematin formation by BHIA assay relative to hemin2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID158043In vitro growth inhibition as IC50 against chloroquine-resistant Plasmodium falciparum FcB11997Journal of medicinal chemistry, Jun-06, Volume: 40, Issue:12
Toward a novel metal-based chemotherapy against tropical diseases. 3. Synthesis and antimalarial activity in vitro and in vivo of the new gold-chloroquine complex [Au(PPh3)(CQ)]PF6.
AID1275424Cytotoxicity against monkey kidney Vero cells by resazurin assay2016European journal of medicinal chemistry, Feb-15, Volume: 109Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
AID1472097Cytotoxicity against CHO cells by MTT assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID220906Inhibition of beta-hematin formation; Yes2001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents.
AID1150092Binding affinity to calf thymus DNA assessed as melting temperature at 10'-5 M by thermal denaturation assay1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.
AID1349119Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by SRB assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Design and synthesis of novel quinacrine-[1,3]-thiazinan-4-one hybrids for their anti-breast cancer activity.
AID1067823Binding affinity to calf thymus DNA at 5:1 DNA to compound ratio by spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID1201321Antimalarial activity against Plasmodium berghei str. ANKA infected in Swiss albino mouse assessed as parasitemia at 0.048 mmol/kg/day, po qd for 3 days by microscopic analysis relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents.
AID442676Cytotoxicity against human MDA-MB-231 cells after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID1201324Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum RKL9 infected in human RBC assessed as effect on schizont maturation after 24 hrs by Geimsa staining-based assay2015European journal of medicinal chemistry, Apr-13, Volume: 94New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents.
AID357311Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by [3H]hypoxanthine uptake2001Journal of natural products, Aug, Volume: 64, Issue:8
Phomoxanthones A and B, novel xanthone dimers from the endophytic fungus Phomopsis species.
AID1652014Antimalarial activity against Plasmodium yoelii BY265RFP infected in Kunming mouse assessed as inhibition of parasitemia at 10 mg/kg/day, ig administered for 4 days starting from 3 hrs post infection and measured at 4 days post infection by Wright-Giemsa
AID1067858n-octanol-PBS buffer distribution coefficient, log D of the compound at pH 7.4 after 24 hrs by HPLC analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID355907Antimalarial activity against multidrug-resistant Plasmodium falciparum K12003Journal of natural products, May, Volume: 66, Issue:5
Antimalarial dihydroisocoumarins produced by Geotrichum sp., an endophytic fungus of Crassocephalum crepidioides.
AID343465Antimalarial curative activity at day 30 against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 30 mg/kg/day peroral dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID442674Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID356616Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 infected erythrocytes by [3H]hypoxanthine uptake2003Journal of natural products, Nov, Volume: 66, Issue:11
Enhancement of the antiplasmodial activity of quassin by transformation into a gamma-lactone.
AID443094Antimalarial activity against chloroquine-resistant Plasmodium falciparum K1 (Thailand) assessed as growth inhibition by [3H]hypoxanthine incorporation assay relative to artemisinin2010Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2
Modular synthesis and in vitro and in vivo antimalarial assessment of C-10 pyrrole mannich base derivatives of artemisinin.
AID445075Antimalarial activity against Plasmodium berghei ANKA infected in Swiss albino mice (Mus musculus) assessed as suppression of parasitemia at 8 mg/kg/day, perorally for 4 days2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID1067827Binding affinity to Escherichia coli pUC18 DNA by fluorescence spectrophotometric analysis2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID343471Antimalarial activity as survival time against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 3 mg/kg/day subcutaneous dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID378703Antimalarial activity against multidrug-resistant Plasmodium falciparum K1 by [3H]hypoxanthine uptake1999Journal of natural products, Feb, Volume: 62, Issue:2
Norpregnane glycosides from a Thai soft coral, Scleronephthya pallida.
AID377562Antimalarial activity after 48 hrs against chloroquine-resistant Plasmodium falciparum K1 by LDH reporter assay2000Journal of natural products, Sep, Volume: 63, Issue:9
Activity of extracts and isolated naphthoquinones from Kigelia pinnata against Plasmodium falciparum.
AID1237968Antitrypanosomal activity against Trypanosoma brucei brucei CMP infected in Swiss mouse assessed as cure rate at 100 umol/kg, ip administered as single dose2015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
New heterocyclic compounds: Synthesis and antitrypanosomal properties.
AID357916Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum FcM29 after 72 hrs by [3H]hypoxanthine uptake2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID152004In vitro inhibitory activity against chloroquine-sensitive Plasmodium falciparum K12001Journal of medicinal chemistry, Sep-13, Volume: 44, Issue:19
Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents.
AID343464Antimalarial activity a survival time in Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 30 mg/kg/day peroral dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID641008Antimalarial activity against Plasmodium berghei ANKA infected in Kunming mouse assessed as mouse survival at 10 mg/kg, ip for 4 days measured on day 102012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent.
AID253013Mean survival time taken as number of days before illness due to Plasmodium berghei when mice (Mus musculus) treated with 10 mg/kg dose for 4 days; g=mice (Mus musculus) survived the test2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID252237Parasitaemia for Plasmodium falciparum in human erythrocytes after 3 hrs incubation with 100 uM compound2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID1152803Antiplasmodial activity against multi-drug resistant Plasmodium falciparum K1 in human erythrocytes assessed as growth inhibition after 48 hrs by optical microscopy2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
Antiplasmodial activity of synthetic ellipticine derivatives and an isolated analog.
AID343458Cytotoxicity against human K562 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1194356Antimalarial activity against chloroquine-susceptible Plasmodium falciparum african D6 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID1077196Cytotoxicity against CHO cells after 48 hrs by MTT assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID360825Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum HB3 after 48 hrs by LDH reporter activity2002Journal of natural products, Jul, Volume: 65, Issue:7
Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicine.
AID1678810Antimalarial activity against chloroquine resistant Plasmodium falciparum RKL9 assessed as reduction in schizont maturation incubated for 24 hrs by Giemsa staining based assay2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
An epigrammatic status of the '
AID1067864Antiplasmodial activity against chloroquine-resistant asexual erythrocytic stage of Plasmodium falciparum Dd2 assessed as parasite growth inhibition by lactate dehydrogenase assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID363641Cytotoxicity against human 184B5 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID1057139Antimalarial activity against drug-resistant Plasmodium falciparum C235 after 72 hrs by SYBR green I staining-based fluorescence assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID343469Antimalarial activity as survival time against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 10 mg/kg/day subcutaneous dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID343459Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 100 mg/kg peroral dose after 3 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID252935Relative IC50 ratio against Plasmodium falciparum F32 compared to chloroquine diphosphate2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID252238In vivo antimalarial activity of compound against Plasmodium berghei in mice (Mus musculus) at dose of 10 mg/kg treated for 4 days2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID1472094Antiplasmodial activity against chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF54 after 48 hrs by NBT dye based LDH assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID1534796Anti-plasmodial activity against Plasmodium berghei ANKA infected in mouse assessed as suppression in blood parasitemia level at 0.048 mmol/kg/day, po administered as single dose at 24 hrs time interval from day 1 to day 3 and measured 96 hrs post infecti2019European journal of medicinal chemistry, Feb-01, Volume: 163Synthesis, in silico experiments and biological evaluation of 1,3,4-trisubstituted pyrazole derivatives as antimalarial agents.
AID343457Cytotoxicity against human HMEC1 cells by MTT assay2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID1077198Antiplasmodial activity against asexual erythrocytic stage of chloroquine-resistant Plasmodium falciparum Dd2 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID377565Selectivity ratio of ED50 for KB cells to IC50 for Plasmodium falciparum T9-962000Journal of natural products, Sep, Volume: 63, Issue:9
Activity of extracts and isolated naphthoquinones from Kigelia pinnata against Plasmodium falciparum.
AID442682Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay in presence of 0.04 uM (E)-5-(benzo[d]thiazol-2-yl)-3-ethyl-2-(2-(methyl(phenyl)amino)vinyl)-1-phenyl-1H-benzo[d]imidazol-3-ium iodide2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID445069Selectivity ratio, CC50 for human HeLa cells to IC50 for Plasmodium falciparum RKL092010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID343460Antimalarial activity as survival time in Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 100 mg/kg peroral dose after 3 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID1727697Antitumor activity against human NCI-H460 cells xenografted in nude BABL/c mouse assessed as tumor growth inhibition at 10 mg/kg, po administered once daily and measured every two days by caliper method relative to control2021European journal of medicinal chemistry, Jan-01, Volume: 209Synthesis and evaluation of new compounds bearing 3-(4-aminopiperidin-1-yl)methyl magnolol scaffold as anticancer agents for the treatment of non-small cell lung cancer via targeting autophagy.
AID247780In vitro antiplasmodial activity for Plasmodium falciparum2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID442683Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay in presence of 0.4 uM 1-(1-(4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)benzyl)piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID1237972Antitrypanosomal activity against Trypanosoma brucei brucei CMP infected in Swiss mouse assessed as parasite number level ul of blood at 100 umol/kg, ip administered as single dose measured on day 22015Bioorganic & medicinal chemistry, Aug-15, Volume: 23, Issue:16
New heterocyclic compounds: Synthesis and antitrypanosomal properties.
AID1456549Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasitic LDH activity after 48 hrs by Malstat reagent based spectrofluorometric method
AID445067Selectivity ratio of CC50 for human HeLa cells to IC50 for Plasmodium falciparum MRC-022010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID343771Inhibition of CYP3A4 at 3 uM2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID363631Cytotoxicity against human MDA-MB-231 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID1067861Cytotoxicity against human HeLa cells assessed as growth inhibition by MTT assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID490222Antimalarial activity against chloroquine-sensitive Plasmodium berghei ANKA infected in Swiss mice (Mus musculus) assessed as suppression of parasitaemia at 5 mg/kg, perorally for 4 days measured on day 5 relative to control2010Bioorganic & medicinal chemistry letters, Jul-15, Volume: 20, Issue:14
In vitro and in vivo antimalarial evaluation of semi-synthetic derivatives of gomphostenin.
AID1638534Antimalarial activity against Plasmodium falciparum W2 pretreated for 24 hrs followed by [3H]-hypoxanthine addition and measured after 24 hrs by [3H]-hypoxanthine growth inhibition assay2019Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5
3,3'-Disubstituted 5,5'-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity.
AID360826Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 after 48 hrs by LDH activity2002Journal of natural products, Jul, Volume: 65, Issue:7
Isolation and in vitro antiplasmodial activities of alkaloids from Teclea trichocarpa: in vivo antimalarial activity and X-ray crystal structure of normelicopicine.
AID1201322Antimalarial activity against Plasmodium berghei str. ANKA infected in Swiss albino mouse assessed as supression of parasitemia at 0.048 mmol/kg/day, po qd for 3 days by microscopic analysis relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents.
AID343466Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 10 mg/kg/day peroral dose over 4 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID363626Cytotoxicity against human MDA-MB-468 cells by SRB assay2008Bioorganic & medicinal chemistry, Sep-01, Volume: 16, Issue:17
The efficacy and selectivity of tumor cell killing by Akt inhibitors are substantially increased by chloroquine.
AID379452Antiplasmodial activity after 36 hrs against chloroquine-resistant Plasmodium falciparum W2 in human erythrocytes by [3H]hypoxanthine uptake1999Journal of natural products, Apr, Volume: 62, Issue:4
10'-Hydroxyusambarensine, a new antimalarial bisindole alkaloid from the roots of Strychnos usambarensis.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1194355Antimalarial activity against chloroquine-resistant Plasmodium falciparum indochina W2 assessed as [3H]-hypoxanthine incorporation by liquid scintillation counting analysis2015Bioorganic & medicinal chemistry, May-01, Volume: 23, Issue:9
Investigation into novel thiophene- and furan-based 4-amino-7-chloroquinolines afforded antimalarials that cure mice.
AID442672Cytotoxicity against human MDA-MB-468 cells after 48 hrs by SRB assay in presence of 0.04 uM (E)-5-(benzo[d]thiazol-2-yl)-3-ethyl-2-(2-(methyl(phenyl)amino)vinyl)-1-phenyl-1H-benzo[d]imidazol-3-ium iodide2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID576507Antiplasmodial activity against Plasmodium falciparum 3D7 infected in RBCs by firefly luciferase reporter gene assay2010Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9
Discovery of potent small-molecule inhibitors of multidrug-resistant Plasmodium falciparum using a novel miniaturized high-throughput luciferase-based assay.
AID759715Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
4-Amino-7-chloroquinolines: probing ligand efficiency provides botulinum neurotoxin serotype A light chain inhibitors with significant antiprotozoal activity.
AID357919Selectivity index, ratio of ED50 for human HeLa cells to IC50 for Plasmodium falciparum Nigerian after 24 hrs by [3H]hypoxanthine incorporation assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID459100Antiplasmodial activity in chloroquine-sensitive Plasmodium berghei ANKA infected BALB/c mice (Mus musculus) assessed as mean parasitemia at 10 mg/kg, intraperitoneally daily once for 4 days2010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID494643Resistance index, ratio of IC50 for Plasmodium falciparum 3D7 to IC50 for Plasmodium falciparum RKL92010Bioorganic & medicinal chemistry letters, Aug-01, Volume: 20, Issue:15
Synthesis of novel alpha-pyranochalcones and pyrazoline derivatives as Plasmodium falciparum growth inhibitors.
AID379451Antiplasmodial activity after 36 hrs against chloroquine-sensitive Plasmodium falciparum FCA 20 in human erythrocytes by [3H]hypoxanthine uptake1999Journal of natural products, Apr, Volume: 62, Issue:4
10'-Hydroxyusambarensine, a new antimalarial bisindole alkaloid from the roots of Strychnos usambarensis.
AID1472095Antiplasmodial activity against chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum Dd2 after 48 hrs by NBT dye based LDH assay2017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID1359611Antiplasmodial activity against Plasmodium berghei ANKA infected in mouse assessed as inhibition of parasitemia at 3 mg/kg/day, po for 4 consecutive days starting from 2 hrs post infection by MSF assay relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1430058Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 after 72 hrs by SYBR Green-1 staining based fluorescence assay
AID253247In vivo antimalarial activity of compound against Plasmodium berghei was determined as suppression of parasitaemia in mice (Mus musculus) at 10 mg/kg treated for 4 days2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID343453Antimalarial activity against chloroquine-sensitive Plasmodium falciparum NF54 by [3H]hypoxanthine uptake2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID641004Antimalarial activity against Plasmodium berghei ANKA infected in Kunming mouse assessed as reduction of parasitemia at 10 mg/kg, ip for 4 days measured on day 52012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Design and synthesis of small molecular dual inhibitor of falcipain-2 and dihydrofolate reductase as antimalarial agent.
AID1067865Antiplasmodial activity against chloroquine-sensitive asexual erythrocytic stage of Plasmodium falciparum D10 assessed as parasite growth inhibition by lactate dehydrogenase assay2014Journal of medicinal chemistry, Jan-23, Volume: 57, Issue:2
Quinoline-pyrimidine hybrids: synthesis, antiplasmodial activity, SAR, and mode of action studies.
AID459109Therapeutic index, Cytotoxicity against human KB cells to Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D102010Bioorganic & medicinal chemistry letters, Feb-01, Volume: 20, Issue:3
Synthesis and evaluation of phenylequine for antimalarial activity in vitro and in vivo.
AID249426Ratio of cytotoxic to that of antiplasmodial activity was determined2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID442687Cytotoxicity against human 184B5 cells after 48 hrs by SRB assay in presence of 0.04 uM (E)-5-(benzo[d]thiazol-2-yl)-3-ethyl-2-(2-(methyl(phenyl)amino)vinyl)-1-phenyl-1H-benzo[d]imidazol-3-ium iodide2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID765571Toxicity in RBC (unknown origin) assessed as hemolysis after 48 hrs at 20 to 80 ug/ml by spectrophotometry2013European journal of medicinal chemistry, Sep, Volume: 67Synthesis of novel analogs of 2-pyrazoline obtained from [(7-chloroquinolin-4-yl)amino]chalcones and hydrazine as potential antitumor and antimalarial agents.
AID343461Antimalarial activity as reduced parasitaemia against Plasmodium berghei ANKA infected NMRI mice (Mus musculus) at 30 mg/kg subcutaneous dose after 3 days2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID1275408Selectivity index, ratio of CC50 for monkey kidney VERO cells to IC50 for chloroquine sensitive Plasmodium falciparum 3D7 infected in human erythrocytes2016European journal of medicinal chemistry, Feb-15, Volume: 109Identification of β-Amino alcohol grafted 1,4,5 trisubstituted 1,2,3-triazoles as potent antimalarial agents.
AID445074Inhibition of beta-hematin formation by BHIA assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines.
AID247907Cytotoxicity against MAC15A mouse adenocarcinomas of the colon cells2005Journal of medicinal chemistry, Apr-07, Volume: 48, Issue:7
Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action.
AID343452Antimalarial activity against chloroquine-resistant Plasmodium falciparum W2 by LDH assay2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Antimalarial activity of novel pyrrolizidinyl derivatives of 4-aminoquinoline.
AID1057137Antimalarial activity against liver stage Plasmodium berghei ANKA sporozoites infected in human HepG2 cells after 48 hrs by luciferase reporter gene assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
3,5-bis(benzylidene)-4-piperidones and related N-acyl analogs: a novel cluster of antimalarials targeting the liver stage of Plasmodium falciparum.
AID1077199Antiplasmodial activity against asexual erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54 assessed as parasite growth inhibition after 48 hrs by lactate dehydrogenase assay2014European journal of medicinal chemistry, Apr-09, Volume: 76Synthesis, in vitro antiplasmodial activity and cytotoxicity of a series of artemisinin-triazine hybrids and hybrid-dimers.
AID1472098Resistance index, ratio of IC50 for chloroquine-resistant synchronized trophozoite stage of Plasmodium falciparum 7G8 to IC50 for chloroquine-sensitive synchronized trophozoite stage of Plasmodium falciparum NF542017Journal of medicinal chemistry, 12-28, Volume: 60, Issue:24
4-Aminoquinoline Antimalarials Containing a Benzylmethylpyridylmethylamine Group Are Active against Drug Resistant Plasmodium falciparum and Exhibit Oral Activity in Mice.
AID357920Selectivity index, ratio of ED50 for human HeLa cells to IC50 for Plasmodium falciparum Nigerian after 72 hrs by [3H]hypoxanthine incorporation assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID442681Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID1359638Drug encapsulation in liposomes assessed as encapsulation efficiency in citrate/phosphate buffered measured after ultracentrifugation using compound addition to preformed liposomes by UV/Vis spectroscopy relative to untreated control2018European journal of medicinal chemistry, May-25, Volume: 152Structure-activity relationship of new antimalarial 1-aryl-3-susbtituted propanol derivatives: Synthesis, preliminary toxicity profiling, parasite life cycle stage studies, target exploration, and targeted delivery.
AID442690Cytotoxicity against human 184B5 cells after 48 hrs by SRB assay in presence of 0.5 uM 2-morpholino-8-phenyl-4H-chromen-4-one2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID252934Relative IC50 ratio against Plasmodium falciparum W2 compared to chloroquine diphosphate2004Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21
Toward a novel metal-based chemotherapy against tropical diseases. 7. Synthesis and in vitro antimalarial activity of new gold-chloroquine complexes.
AID1201323Antimalarial activity against Plasmodium berghei str. ANKA infected in Swiss albino mouse assessed as survival at 0.048 mmol/kg/day, po qd for 3 days by microscopic analysis relative to control2015European journal of medicinal chemistry, Apr-13, Volume: 94New heterocyclic hybrids of pyrazole and its bioisosteres: design, synthesis and biological evaluation as dual acting antimalarial-antileishmanial agents.
AID442684Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay in presence of 3.5 uM 4-(2-chloro-10H-phenoxazin-10-yl)-N,N-diethylbutan-1-amine hydrochloride2010European journal of medicinal chemistry, Feb, Volume: 45, Issue:2
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
AID357915Antiplasmodial activity after 24 hrs against chloroquine-resistant Plasmodium falciparum FcM29 by [3H]hypoxanthine uptake2001Journal of natural products, Sep, Volume: 64, Issue:9
Bioactive acridone alkaloids from Swinglea glutinosa.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1347153Confirmatory screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347152Confirmatory screen NINDS AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347161Confirmatory screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1529187Binding affinity to human serum albumin assessed as change in dissociation constant pKa2 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1529186Binding affinity to human serum albumin assessed as change in dissociation constant pKa1 of compound in aqueous medium to presence of human serum albumin by UV-pH titration based spectrophotometric analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1167710Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for chloroquine-sensitive Plasmodium falciparum2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID136445Antispasmodic activity evaluated as percentage reduction in the contractile response of the estrous uterus in mouse1981Journal of medicinal chemistry, Jun, Volume: 24, Issue:6
Synthesis and preliminary pharmacological evaluation of asymmetric chloroquine analogues.
AID1167707Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 by Malaria SYBR Green I-nucleic acid staining based fluorescence assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID1529182Protein binding in plasma (unknown origin)2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1167708Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum K1 by Malaria SYBR Green I-nucleic acid staining based fluorescence assay2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID311524Oral bioavailability in human2007Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24
Hologram QSAR model for the prediction of human oral bioavailability.
AID1529184Protein binding in immobilized human serum albumin by HPLC analysis2020Journal of medicinal chemistry, 02-27, Volume: 63, Issue:4
Human Serum Albumin Binding in a Vial: A Novel UV-pH Titration Method To Assist Drug Design.
AID1167721Binding affinity to hematin in 40% aqueous DMSO and 20 mM HEPES buffer at pH 7.5 at 25 degC2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID1167709Resistance index, ratio of IC50 for chloroquine-resistant Plasmodium falciparum K1 to IC50 for chloroquine-sensitive Plasmodium falciparum 3D72014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID1167712Antimalarial activity against chloroquine-resistant Plasmodium yoelii N-67infected in Swiss Albino mouse assessed as suppression of parasitemia at 100 mg/kg, po once daily for 7 days measured on day 4 post infection2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID1167716Antimalarial activity against chloroquine-resistant Plasmodium yoelii N-67infected in Swiss Albino mouse assessed as mouse cured on day 28 at 100 mg/kg, po once daily for 7 days measured on day 4 post infection2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID1167711Binding affinity to heme assessed as inhibition of 1-oleoyl-rac-glycerol-induced beta-hematin polymerization by UV spectrophotometry2014Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21
Synthesis of chiral chloroquine and its analogues as antimalarial agents.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID558302Antiviral activity against Human coronavirus OC43 infected in pregnant C57BL/6 mouse assessed as survival rate at 5 mg/kg, sc administered postpartum2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID1225969Antiplasmodial activity against Plasmodium falciparum 3D7 infected in O positive erythrocytes assessed as inhibition of parasite growth by FACS-based assay2015European journal of medicinal chemistry, May-05, Volume: 95A natural product based DOS library of hybrid systems.
AID159481In vitro inhibition of Plasmodium falciparum at 64 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID159476In vitro inhibition of Plasmodium falciparum at 4 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159475In vitro inhibition of Plasmodium falciparum at 32 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID320725Relative chloroquine IC50 for beta-hematin formation2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Pharmacomodulation on the 3-acetylursolic acid skeleton: Design, synthesis, and biological evaluation of novel N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-3-O-acetylursolamide derivatives as antimalarial agents.
AID159313In vitro antimalarial activity for Plasmodium falciparum at 1 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159318In vitro antimalarial activity for Plasmodium falciparum at 2 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558299Antiviral activity against Human coronavirus OC43 infected in pregnant C57BL/6 mouse assessed as survival rate at 15 mg/kg, sc administered prepartum2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID1573776Antimalarial activity against ring stage Plasmodium falciparum 3D7 infected in type A-positive human erythrocytes after 72 hrs by SYBR green 1 dye-based fluorescence assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis of new betulinic acid/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities.
AID1493587Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 incubated for 48 hrs by malstat reagent based LDH release assay
AID159457In vitro antimalarial activity for chloroquine-resistant Plasmodium falciparum at 64 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159458In vitro antimalarial activity for chloroquine-resistant Plasmodium falciparum at 8 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID320724Inhibition of beta-hematin formation2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Pharmacomodulation on the 3-acetylursolic acid skeleton: Design, synthesis, and biological evaluation of novel N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-3-O-acetylursolamide derivatives as antimalarial agents.
AID159474In vitro inhibition of Plasmodium falciparum at 2 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159607In vitro inhibition of chloroquine-resistant Plasmodium falciparum at 64u M/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159602In vitro inhibition of chloroquine-resistant Plasmodium falciparum at 2 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID1870335Antiplasmodial activity against CQ-resistance Plasmodium falciparum W2 infected in A+ human blood assessed as reduction in parasite growth measured after 72 hrs by HRP2 ELISA2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids.
AID558306Antiviral activity against Human coronavirus OC43 infected in new born C57BL/6 mouse assessed as survival rate at 15 mg/kg, sc transfered via maternal milk after administration to pregnant mouse2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID320717Inhibition of beta-hematin formation at 5 mM2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Pharmacomodulation on the 3-acetylursolic acid skeleton: Design, synthesis, and biological evaluation of novel N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-3-O-acetylursolamide derivatives as antimalarial agents.
AID558308Antiviral activity against Human coronavirus OC43 infected in new born C57BL/6 mouse assessed as survival rate at 5 mg/kg, sc transfered via maternal milk after administration to pregnant mouse2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID159604In vitro inhibition of chloroquine-resistant Plasmodium falciparum at 4 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558307Antiviral activity against Human coronavirus OC43 infected in new born C57BL/6 mouse assessed as survival rate at 5 mg/kg, sc transfered via placenta after administration to pregnant mouse2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID159464In vitro inhibition of Plasmodium falciparum at 1.0 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159334In vitro antimalarial activity for chloroquine-resistant Plasmodium falciparum at 1 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159327In vitro antimalarial activity for Plasmodium falciparum at 8 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558305Antiviral activity against Human coronavirus OC43 infected in new born C57BL/6 mouse assessed as survival rate at 15 mg/kg, sc transfered via placenta after administration to pregnant mouse2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID1870341Binding affinity to hemin (unknown origin) assessed as inhibition of hemozoin formation in pH 7.4 buffer by HPLC analysis2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids.
AID159320In vitro antimalarial activity for Plasmodium falciparum at 4 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID1870339Resistance index, ratio of IC50 for antiplasmodial activity against CQ-resistance Plasmodium falciparum W2 infected in A+ human blood to IC50 for antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 infected in A+ human blood2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids.
AID558297Selectivity index, ratio of CC50 for human HRT18 cells to EC50 for Human coronavirus OC43 infected in human HRT18 cells2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID558295Antiviral activity against Human coronavirus OC43 infected in human HRT18 cells after 4 days by qRT-PCR analysis2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID558298Antiviral activity against Human coronavirus OC43 infected in human HRT18 cells assessed as decrease in viral load at 10 uM treated at the time of infection measured after 28 hrs by qRT-PCR analysis relative to control2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID159333In vitro antimalarial activity for chloroquine-resistant Plasmodium falciparum at 16 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID1870340Binding affinity to hemin (unknown origin) assessed as inhibition of hemozoin formation in pH 5.6 buffer by HPLC analysis2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids.
AID159482In vitro inhibition of Plasmodium falciparum at 8 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159598In vitro inhibition of chloroquine-resistant Plasmodium falciparum at 1 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558303Antiviral activity against Human coronavirus OC43 infected in pregnant C57BL/6 mouse assessed as survival rate at 1 mg/kg, sc administered prepartum2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID159337In vitro antimalarial activity for chloroquine-resistant Plasmodium falciparum at 2 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID159603In vitro inhibition of chloroquine-resistant Plasmodium falciparum at 32 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID397125Antimalarial activity against Plasmodium falciparum
AID320718Inhibition of beta-hematin formation at 10 mM2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Pharmacomodulation on the 3-acetylursolic acid skeleton: Design, synthesis, and biological evaluation of novel N-{3-[4-(3-aminopropyl)piperazinyl]propyl}-3-O-acetylursolamide derivatives as antimalarial agents.
AID159608In vitro inhibition of chloroquine-resistant Plasmodium falciparum at 8 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558301Antiviral activity against Human coronavirus OC43 infected in pregnant C57BL/6 mouse assessed as survival rate at 5 mg/kg, sc administered prepartum2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID558296Cytotoxicity against human HRT18 cells after 4 days by MTS assay2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID159467In vitro inhibition of Plasmodium falciparum at 16 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558309Antiviral activity against Human coronavirus OC43 infected in new born C57BL/6 mouse assessed as survival rate at 1 mg/kg, sc transfered via placenta after administration to pregnant mouse2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID159597In vitro inhibition of chloroquine-resistant Plasmodium falciparum at 16 uM/well dose at 72 hrs in total parasite growth assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159326In vitro antimalarial activity for Plasmodium falciparum at 64 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558310Antiviral activity against Human coronavirus OC43 infected in new born C57BL/6 mouse assessed as survival rate at 1 mg/kg, sc transfered via maternal milk after administration to pregnant mouse2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID1573775Antiviral activity against recombinant HCMV AD169 expressing GFP infected in human foreskin fibroblasts measured after 7 days by GFP-based multi-round replication assay2019Bioorganic & medicinal chemistry, 01-01, Volume: 27, Issue:1
Synthesis of new betulinic acid/betulin-derived dimers and hybrids with potent antimalarial and antiviral activities.
AID159312In vitro antimalarial activity for Plasmodium falciparum at 16 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159338In vitro antimalarial activity for chloroquine-resistant Plasmodium falciparum at 32 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID159454In vitro antimalarial activity for chloroquine-resistant Plasmodium falciparum at a dose of 4 uM/well through Schizonts maturation assay over 24 hr1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID1870334Antiplasmodial activity against CQ-susceptible Plasmodium falciparum 3D7 infected in A+ human blood assessed as reduction in parasite growth measured after 72 hrs by HRP2 ELISA2022ACS medicinal chemistry letters, Jul-14, Volume: 13, Issue:7
Synthesis, Anti-Plasmodial Activities, and Mechanistic Insights of 4-Aminoquinoline-Triazolopyrimidine Hybrids.
AID558300Antiviral activity against Human coronavirus OC43 infected in pregnant C57BL/6 mouse assessed as survival rate at 15 mg/kg, sc administered postpartum2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID159319In vitro antimalarial activity for Plasmodium falciparum at 32 uM/well dose at 24 hrs in Schizont maturation assay1999Bioorganic & medicinal chemistry letters, Mar-08, Volume: 9, Issue:5
Antimalarial activity of 3-hydroxyalkyl-2-methylene-propionic acid derivatives.
AID558304Antiviral activity against Human coronavirus OC43 infected in pregnant C57BL/6 mouse assessed as survival rate at 1 mg/kg, sc administered postpartum2009Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8
Antiviral activity of chloroquine against human coronavirus OC43 infection in newborn mice.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (490)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990232 (47.35)18.7374
1990's49 (10.00)18.2507
2000's73 (14.90)29.6817
2010's91 (18.57)24.3611
2020's45 (9.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.03

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.03 (24.57)
Research Supply Index6.32 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index47.56 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.03)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials24 (4.54%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews15 (2.84%)6.00%
Reviews0 (0.00%)6.00%
Reviews1 (9.09%)6.00%
Case Studies55 (10.40%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other435 (82.23%)84.16%
Other6 (100.00%)84.16%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (56)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum [NCT03083847]Phase 155 participants (Actual)Interventional2017-06-05Completed
A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border [NCT01074905]Phase 3655 participants (Actual)Interventional2010-05-31Completed
Clinical Trial for Evaluation of Ethnic Differences in Pharmacokinetics of Chloroquine, an Anti-malarial Drug [NCT01366235]Phase 110 participants (Actual)Interventional2011-05-31Completed
Monitoring Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax Based on Clinical, Parasitologic and Hematologic Parameters in Shecha Health Center: Open Label Clinical Trial [NCT06044805]Phase 4100 participants (Actual)Interventional2022-12-19Completed
A Phase 1, Open-Label, Randomized, Single Dose, Parallel Design Study To Estimate The Relative Bioavailability Of Co Administered Formulations Of Azithromycin Microsphere (AZ) And Chloroquine Test Formulation (CQ) Compared With Co Administered Immediate R [NCT01100060]Phase 140 participants (Actual)Interventional2010-04-30Completed
Identification of Pre-erythrocytic Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis [NCT02080026]15 participants (Actual)Interventional2014-06-30Completed
Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area [NCT02118090]Phase 473 participants (Actual)Interventional2014-05-31Completed
Phase II, Randomized, Double-blind, Controlled Clinical Trial Evaluating the Efficacy and Safety of Chloroquine + Low Dose Losartan Compared to Chloroquine Monotherapy in Subjects With SARS-CoV-2 Pneumonia [NCT04428268]Phase 20 participants (Actual)Interventional2020-03-10Withdrawn(stopped due to evidence showed chloroquine is not effective against COVID-19)
A Randomised, Double-blind, Placebo Controlled Trial of Chloroquine for the Prevention of Influenza [NCT01078779]Phase 21,516 participants (Actual)Interventional2009-11-30Active, not recruiting
A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil [NCT01107145]Phase 416 participants (Actual)Interventional2011-02-28Terminated(stopped due to Extremely slow enrollment)
Safety and Efficacy of Different Regimens of Primaquine on Vivax Malaria Treatment in Glucose 6-phosphate Dehydrogenase Deficient Patients [NCT03529396]Phase 2106 participants (Actual)Interventional2018-07-20Active, not recruiting
Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan [NCT01178021]Phase 4593 participants (Actual)Interventional2009-08-31Completed
Efficacy and Safety of Prednisolone and Chloroquine Add on Therapy in Osteoarthritis of the Knee Treated With Fixed Dose Combination of Glucosamine and Chondroitin Sulfate. [NCT00805519]Phase 4230 participants (Actual)Interventional2009-02-28Completed
A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine In He [NCT00844207]Phase 140 participants (Actual)Interventional2009-02-28Completed
A Phase 1 Study of Chloroquine in Combination With Carboplatin/Gemcitabine in Advanced Solid Tumors [NCT02071537]Phase 124 participants (Actual)Interventional2014-05-13Completed
[NCT02058173]Phase 410 participants (Actual)Interventional2014-01-31Completed
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falciparum I [NCT03952650]Phase 1/Phase 2252 participants (Actual)Interventional2019-05-23Completed
Genotoxic Stress, Atherosclerosis, and Metabolic Syndrome-AIM 2 [NCT00455325]Phase 235 participants (Actual)Interventional2004-09-30Completed
Evaluating the Potential Role of Chloroquine in Preventing Infections During Elimination Campaigns: A Randomized, Single-blind, Placebo-controlled Trial in Asymptomatic Mozambican Adults [NCT02698748]Phase 2/Phase 375 participants (Actual)Interventional2015-01-31Completed
Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria in Eastern Indonesia of Two Plasmodium Falciparum Sporozoite Vaccines, Sanaria® PfSPZ Vaccine and Sanaria® PfSPZ-CVac: A Randomized, Double-Blind, Placebo-C [NCT03503058]Phase 2372 participants (Anticipated)Interventional2022-05-07Recruiting
A Randomized, Pilot Study of the Anti-Viral and Anti-Inflammatory Effects of Chloroquine in Early HIV Infection [NCT00308620]Phase 2/Phase 313 participants (Actual)Interventional2006-03-31Terminated(stopped due to Insufficient financial support; lack of efficacy for primary endpoint)
Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection [NCT02691910]Phase 2/Phase 3204 participants (Actual)Interventional2014-08-31Completed
Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi [NCT00125489]Phase 4210 participants Interventional2005-05-31Completed
DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS [NCT01980745]Phase 461 participants (Actual)Interventional2002-02-28Completed
Artemether-lumefantrine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi Malaria: a Randomized Open Label Trial in Sabah, Malaysia (CAN KNOW Trial) [NCT02001012]Phase 3123 participants (Actual)Interventional2014-01-31Completed
Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax [NCT01640574]Phase 3680 participants (Actual)Interventional2012-02-29Completed
A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam [NCT04328493]Phase 210 participants (Actual)Interventional2020-04-07Completed
Safety, Tolerability, and Pharmacokinetic Study of Concomitant Chloroquine and Tafenoquine in Healthy Volunteers [NCT00871156]Phase 168 participants (Actual)Interventional2009-03-24Completed
Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study [NCT02932007]Phase 240 participants (Anticipated)Interventional2017-03-28Recruiting
Preventing Invasive Breast Neoplasia With Chloroquine (PINC) Trial [NCT01023477]Phase 1/Phase 212 participants (Actual)Interventional2009-12-31Completed
A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults [NCT01290601]Phase 270 participants (Actual)Interventional2003-09-15Terminated(stopped due to Failure to meet pre-specified endpoint for the day 28 cure rate)
Clinical Study Evaluating the Efficacy of Chloroquine or Hydroxychloroquine in COVID-19 Treatment [NCT04353336]Phase 2/Phase 3194 participants (Actual)Interventional2020-03-23Completed
Phase IIb Study to Evaluate the Efficacy and Safety of Chloroquine Diphosphate in the Treatment of Patients With Comorbidities, Without Severe Acute Respiratory Syndrome, Under the New Coronavirus (SARS-CoV2): a Double-blind, Randomized, Placebo-controlle [NCT04342650]Phase 2152 participants (Actual)Interventional2020-04-08Completed
The Efficacy and Safety of Carrimycin Treatment in Patients With Novel Coronavirus Infectious Disease (COVID-19) : A Multicenter, Randomized, Open-controlled Study [NCT04286503]Phase 4520 participants (Anticipated)Interventional2020-02-23Not yet recruiting
Efficacy and Safety of Chloroquine Diphosphate for the Treatment of Hospitalized Patients With Severe Acute Respiratory Syndrome Secondary to SARS-CoV2: a Phase IIb, Double-blind, Randomized Adaptive Clinical Trial [NCT04323527]Phase 2278 participants (Actual)Interventional2020-03-23Completed
A Phase 2a Open Label Study of the Safety and Efficacy of a Single Dose of Weekly Chloroquine (CQ) and Azithromycin (AZ) Administered in Combination for Malaria Prophylaxis in Healthy Adults Challenged With 7G8 Chloroquine-Resistant Plasmodium Falciparum [NCT03278808]Phase 20 participants (Actual)Interventional2018-09-17Withdrawn(stopped due to The IND has been withdrawn from FDA)
Effect of Antimalarial Drugs on the Immune Response to Rabies Vaccine for Post-exposure Prophylaxis. A Randomized, Open Label, Trial in Healthy US Adults Age 18-60 Years [NCT02564471]Phase 4103 participants (Actual)Interventional2016-11-11Completed
Multicenter, Randomized, Open-label, Non-commercial, Investigator-initiated Study to Evaluate the Efficacy and Safety of Chloroquine Phosphate in Combination With Telemedicine Care in the Risk Reduction of COVID-19 Related Hospitalization or Death, in Amb [NCT04331600]Phase 416 participants (Actual)Interventional2020-04-16Completed
A Phase II/III, Randomized, Comparative Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in India [NCT00074841]Phase 2/Phase 3230 participants (Actual)Interventional2003-09-30Completed
A Phase II, Randomized, Comparative Trial Of Azithromycin In Combination With Chloroquine Versus Chloroquine In The Eradication Of Asymptomatic Plasmodium Falciparum Infection In Semi-Immune Adults [NCT00082563]Phase 214 participants (Actual)Interventional2004-08-31Terminated
A Phase 2/3, Randomized, Comparative, Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia [NCT00084240]Phase 2/Phase 332 participants (Actual)Interventional2004-03-31Terminated(stopped due to See Detailed Description)
Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia [NCT01708876]Phase 3250 participants (Anticipated)Interventional2012-10-31Completed
PARASITIC CLEARANCE AND RECURRENCE RATES AMONG PATIENTS WITH VIVAX MALARIA ON CHLOROQUINE AND PRIMAQUINE THERAPY [NCT01784315]50 participants (Anticipated)Observational [Patient Registry]2013-03-31Recruiting
Prednisone Plus Chloroquine Versus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly in Papua New Guinea: a Randomized Open-label Trial [NCT01785979]Phase 30 participants (Actual)Interventional2016-01-31Withdrawn(stopped due to Lack of funding)
Pharmacokinetic Study of Multi-dose Chloroquine [NCT01814423]Phase 430 participants (Actual)Interventional2013-04-30Completed
An Open-label, Phase I Trial With Expansion Cohort of Nab-Paclitaxel + Gemcitabine + Cisplatin + Botensilimab (AGEN1811) + Balsilimab (AGEN2034) + Chloroquine + Celecoxib in Patients With Previously Untreated Metastatic Pancreatic Cancer [NCT06076837]Phase 112 participants (Anticipated)Interventional2023-12-31Not yet recruiting
IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine in Brain Metastasis Radiotherapy. [NCT01727531]20 participants (Actual)Interventional2008-12-31Completed
WU 352: Open-label, Randomized Controlled Trial of Hydroxychloroquine Alone or Hydroxychloroquine Plus Azithromycin or Chloroquine Alone or Chloroquine Plus Azithromycin in the Treatment of SARS CoV-2 Infection [NCT04341727]Phase 331 participants (Actual)Interventional2020-04-04Terminated(stopped due to DSMB recommended study suspension slow accrual)
Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico [NCT02394197]Phase 4153 participants (Actual)Interventional2008-02-29Completed
An Open Label Cluster Randomized Controlled Trial of Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19 [NCT04362332]Phase 425 participants (Actual)Interventional2020-04-14Terminated(stopped due to Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be expected we need more than 1000 inclusions)
Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial [NCT04344951]Phase 229 participants (Actual)Interventional2020-04-06Terminated(stopped due to No clinical efficacy against SARS-CoV-2 recorded)
Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19? [NCT04447534]Phase 3191 participants (Actual)Interventional2020-06-23Completed
An Investigator-Initiated, Phase II, Randomized, Withdrawal Study of Mycophenolate Mofetil (MMF) in Patients With Stable, Quiescent Systemic Lupus Erythematosus (SLE) [NCT01946880]Phase 2102 participants (Actual)Interventional2013-11-20Terminated(stopped due to Slow enrollment.)
Efficacy of Chloroquine Phosphate Prophylactic Use in First-line Health Personnel Exposed to COVID-19 Patients [NCT04443270]Phase 1200 participants (Anticipated)Interventional2020-07-27Not yet recruiting
A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria. [NCT01376167]Phase 2851 participants (Actual)Interventional2014-04-24Completed
Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial [NCT02463331]Phase 457 participants (Actual)Interventional2003-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00308620 (2) [back to overview]HIV Viral Load Change
NCT00308620 (2) [back to overview]Change in Immune Activation Assessed by Flow Cytometry Analysis From Baseline to 8 Weeks
NCT00455325 (7) [back to overview]Total Cholesterol
NCT00455325 (7) [back to overview]Diastolic Blood Pressure
NCT00455325 (7) [back to overview]Insulin Sensitivity
NCT00455325 (7) [back to overview]Low-density Lipoprotein
NCT00455325 (7) [back to overview]Non-HDL Cholesterol
NCT00455325 (7) [back to overview]Systolic Blood Pressure
NCT00455325 (7) [back to overview]Triglycerides
NCT01023477 (4) [back to overview]Total Number of Treatment-Related Adverse Events
NCT01023477 (4) [back to overview]Impact of Chloroquine Treatment on the Cell Signaling Kinase Levels in DCIS Lesions.
NCT01023477 (4) [back to overview]Average Change in the Longest Diameter of the Breast MRI Target Lesion
NCT01023477 (4) [back to overview]Effect of Chloroquine on Proliferating Cell Nuclear Antigen (PCNA) Proliferation Index
NCT01290601 (5) [back to overview]Fever Clearance Time (FCT)
NCT01290601 (5) [back to overview]Adequate Clinical Response (ACR) of Tafenoquine: 28 Day Cure Rate
NCT01290601 (5) [back to overview]Number of Subjects Without Relapse of P. Vivax
NCT01290601 (5) [back to overview]Parasite and Gametocyte Clearance Time (PCT and GCT)
NCT01290601 (5) [back to overview]Safety and Tolerability of Tafenoquine as Defined by Most Common Adverse Events (AEs)
NCT01376167 (31) [back to overview]Number of Participants With Hematology Laboratory Data Outside the Reference Range
NCT01376167 (31) [back to overview]Number of Participants Who Received Blood Transfusion
NCT01376167 (31) [back to overview]Number of Participants With Acute Renal Failure
NCT01376167 (31) [back to overview]Number of Participants With Recurrence-free Efficacy at 4 Months Post Dose
NCT01376167 (31) [back to overview]Number of Participants With Recurrence-free Efficacy at 6 Months Post Dose
NCT01376167 (31) [back to overview]Oral Clearance (CL/F) of TQ
NCT01376167 (31) [back to overview]Time to Fever Clearance
NCT01376167 (31) [back to overview]Time to Parasite Clearance
NCT01376167 (31) [back to overview]Time to Recurrence of P Vivax Malaria
NCT01376167 (31) [back to overview]Volume of Distribution (Vc/F) of TQ
NCT01376167 (31) [back to overview]Change From Baseline in Percent Methemoglobin
NCT01376167 (31) [back to overview]Cost Associated With Recurrence Episode of P Vivax Malaria
NCT01376167 (31) [back to overview]Cost Associated With Recurrence Episode of P Vivax Malaria
NCT01376167 (31) [back to overview]Cost Incurred With Purchase of Medications Associated With Recurrence Episode of Malaria
NCT01376167 (31) [back to overview]Cost Incurred With Purchase of Medications Associated With Recurrence Episode of Malaria
NCT01376167 (31) [back to overview]Incidence of Visual Field Abnormalities Based on Best Corrected Visual Acuity Test Scores
NCT01376167 (31) [back to overview]Incidence of Visual Field Abnormalities Based on Best Corrected Visual Acuity Test Scores
NCT01376167 (31) [back to overview]Number of Participants With Action Taken to Treat Recurrence Episode of P Vivax Malaria
NCT01376167 (31) [back to overview]Number of Participants With Action Taken to Treat Recurrence Episode of P Vivax Malaria
NCT01376167 (31) [back to overview]Number of Participants With Clinical Chemistry Laboratory Data Outside the Reference Range
NCT01376167 (31) [back to overview]Number of Participants With Gastrointestinal Disorders
NCT01376167 (31) [back to overview]Number of Participants With Hemoglobin Decline From Baseline Over First 29 Days
NCT01376167 (31) [back to overview]Number of Participants With Keratopathy
NCT01376167 (31) [back to overview]Number of Participants With Keratopathy
NCT01376167 (31) [back to overview]Number of Participants With Retinal Changes From Baseline
NCT01376167 (31) [back to overview]Number of Participants With Retinal Changes From Baseline
NCT01376167 (31) [back to overview]Number of Participants With TEAEs and Serious TEAEs
NCT01376167 (31) [back to overview]Number of Participants With TEAEs by Maximum Intensity
NCT01376167 (31) [back to overview]Number of Participants With Treatment Emergent Adverse Events (TEAEs) Potentially Related to Hemoglobin Decrease
NCT01376167 (31) [back to overview]Time Lost by Participants or Care Givers From Normal Occupation
NCT01376167 (31) [back to overview]Time Lost by Participants or Care Givers From Normal Occupation
NCT01946880 (36) [back to overview]Cumulative Excess Systemic Steroid Dose From Time of Clinically Significant Disease Reactivation to Return to Pre-Flare Dose or End of Trial Participation
NCT01946880 (36) [back to overview]The Addition of Aggressive Adjunctive Therapy to Mycophenolate Mofetil (MMF) or Change in MMF Therapy to Cytotoxic Drug Due to Flare by Week 60
NCT01946880 (36) [back to overview]Time to First Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare
NCT01946880 (36) [back to overview]Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT-F) Fatigue Scale (FS): Total Score
NCT01946880 (36) [back to overview]Change From Baseline in the Lupus Quality of Life (QoL)Score
NCT01946880 (36) [back to overview]Change From Baseline in the Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup
NCT01946880 (36) [back to overview]Change From Baseline in the Short Form Health Survey (SF-36) Physical Functioning (PF) Score
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Adverse Events (AEs)
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Adverse Events (AEs) Related to Mycophenolate Mofetil (MMF)
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Adverse Events (AEs) Related to Systemic Lupus Erythematosus (SLE)
NCT01946880 (36) [back to overview]All-Cause Mortality
NCT01946880 (36) [back to overview]Number of Grade 3, 4, or 5 Hematological Adverse Events (AEs).
NCT01946880 (36) [back to overview]Cumulative Systemic Steroid Dose by Week 60
NCT01946880 (36) [back to overview]Mortality Related to Systemic Lupus Erythematosus (SLE)
NCT01946880 (36) [back to overview]Number of Infection-Related Adverse Events (AEs)
NCT01946880 (36) [back to overview]Number of Malignancies Reported as Adverse Events (AEs).
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF<2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup
NCT01946880 (36) [back to overview]Change From Baseline in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index for Systemic Lupus Erythematosus (SLICC/DI): Total Score
NCT01946880 (36) [back to overview]Number of Participants Experiencing Any British Isles Lupus Assessment Group (BILAG) A Flare by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing Clinically Significant Disease Reactivation by Week 60
NCT01946880 (36) [back to overview]Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF <2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup
NCT01946880 (36) [back to overview]Number of Participants in the Lupus Nephritis Subgroup Experiencing a British Isles Lupus Assessment Group (BILAG) A Renal Flare by Week 60
NCT01946880 (36) [back to overview]Number of Serious Adverse Events (SAEs).
NCT01946880 (36) [back to overview]Time From Clinically Significant Disease Reactivation to Improvement in British Isles Lupus Assessment Group (BILAG) From Maximum Level During Flare
NCT01946880 (36) [back to overview]Time From Clinically Significant Disease Reactivation to Recovery to Baseline British Isles Lupus Assessment Group (BILAG) Score or BILAG C
NCT01946880 (36) [back to overview]Time From Clinically Significant Disease Reactivation to Return to Pre-Flare Steroid Dose
NCT01946880 (36) [back to overview]Time to Clinically Significant Disease Reactivation
NCT01946880 (36) [back to overview]Time to First Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare
NCT02463331 (2) [back to overview]Biochemical Response to Therapy
NCT02463331 (2) [back to overview]Histopathological Response to Therapy
NCT02564471 (4) [back to overview]Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group Compared to Control to Determine if a Fifth Dose of PEP Would Add Value
NCT02564471 (4) [back to overview]GMT Over Protective Titer 28 Days Post Fourth Dose of PCECV
NCT02564471 (4) [back to overview]GMT Over Protective Titer Prior Fourth Dose of PCECV
NCT02564471 (4) [back to overview]GMT Over Protective Titer Prior to Third Dose of PCECV
NCT03083847 (4) [back to overview]Number of Participants With P.Falciparum Blood Stage Infection
NCT03083847 (4) [back to overview]Number of Participants With Serious Adverse Events (SAEs)
NCT03083847 (4) [back to overview]Number of Participants Requiring Treatment With Additional Anti-malarial Medication
NCT03083847 (4) [back to overview]Number of Participants With Local and Systemic Adverse Events (AEs)
NCT03952650 (3) [back to overview]Number of Participants With Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03952650 (3) [back to overview]Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT03952650 (3) [back to overview]Number of Participants With Positive Sensitive Blood Smear (sBS)

HIV Viral Load Change

HIV-1 viral load change between baseline and 8 weeks (NCT00308620)
Timeframe: baseline and 8 weeks

Interventionlog10 copies/mL (Log Mean)
Chloroquine 250mg or 500mg-.083
Placebo0.0

[back to top]

Change in Immune Activation Assessed by Flow Cytometry Analysis From Baseline to 8 Weeks

The Change in the percentages of CD38+ HLA-DR+ CD8 and CD4 memory T cells from baseline to 8 weeks. (NCT00308620)
Timeframe: 8 weeks

,
Interventionpercentage change (Median)
CD8 CD38+HLA-DR+CD4 ki67+
Chloroquine 250mg or 500mg-2.5-2.0
Placebo1.851.4

[back to top]

Total Cholesterol

Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.

Interventionmg/dL (Mean)
Placebo Comparator: First Intervention (3 Weeks)187
Second Intervention (3 Weeks)181
Third Intervention (3 Weeks)182
Fourth Intervention (3 Weeks)173

[back to top]

Diastolic Blood Pressure

Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night. Data were analyzed as mean values over 24 hours. (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.

InterventionmmHg (Mean)
Placebo Comparator: First Intervention (3 Weeks)70
Second Intervention (3 Weeks)71
Third Intervention (3 Weeks)73
Fourth Intervention (3 Weeks)73

[back to top]

Insulin Sensitivity

Hepatic insulin sensitivity was measured by comparing glucose production at baseline of zero insulin infusion rate with glucose production at 56 pmol/m2/min. Hepatic insulin sensitivity was expressed as the percent suppression, such that greater percent suppression indicated greater hepatic insulin sensitivity. There are no reference values, since the patients served as their own controls. (NCT00455325)
Timeframe: assessed every 8 - 10 weeks at the end of each treatment period

Intervention% suppression inf rate 56 pmol/m2/min (Mean)
Placebo Comparator: First Intervention (3 Weeks).56
Second Intervention (3 Weeks)0.55
Third Intervention (3 Weeks)0.66
Fourth Intervention (3 Weeks)0.70

[back to top]

Low-density Lipoprotein

Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.

Interventionmg/dl (Mean)
Placebo Comparator: First Intervention (3 Weeks)115
Second Intervention (3 Weeks)109
Third Intervention (3 Weeks)109
Fourth Intervention (3 Weeks)103

[back to top]

Non-HDL Cholesterol

Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.

Interventionmg/dL (Mean)
Placebo Comparator: First Intervention (3 Weeks)144
Second Intervention (3 Weeks)139
Third Intervention (3 Weeks)139
Fourth Intervention (3 Weeks)131

[back to top]

Systolic Blood Pressure

Two techniques were employed: auscultation of seated subjects at rest was performed by a trained observer who recorded the first and fifth phases of the Korotkoff sounds; and, a portable oscillometric device (SpaceLabs Medical) recorded results every 20 min during the day and every hour during the night. Data were analyzed as mean values over 24 hours. (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period

InterventionmmHg (Mean)
Placebo Comparator: First Intervention (3 Weeks)121
Second Intervention (3 Weeks)121
Third Intervention (3 Weeks)123
Fourth Intervention (3 Weeks)123

[back to top]

Triglycerides

Fasting Serum Blood Sample (NCT00455325)
Timeframe: Assessed every 8-10 weeks at the end of each treatment period.

Interventionmg/dL (Mean)
Placebo Comparator: First Intervention (3 Weeks)143
Second Intervention (3 Weeks)153
Third Intervention (3 Weeks)151
Fourth Intervention (3 Weeks)140

[back to top] [back to top]

Impact of Chloroquine Treatment on the Cell Signaling Kinase Levels in DCIS Lesions.

"The study evaluated the effect of chloroquine treatment on the proteomic signaling profiles of the DCIS lesions. Post treatment surgical specimens were evaluated by immunohistochemical staining to measure cell signaling kinase levels for CD68 and HMGB1. CD68 (Cluster Determinant 68) is a marker of macrophages/monocytes in the breast ducts. and HMGB1 (High Mobility Group Box 1) is involved in oxidative stress-mediated autophagy. HMGB1 is a non-histone DNA binding protein. The number of positive cells were quantified and recorded.~." (NCT01023477)
Timeframe: At the time of surgery

,
InterventionPositive cells (Mean)
HMGB1CD68
Chloroquine Low Dose (250mg/Week)47.89163.2
Chloroquine Standard Dose (500mg/Week)33.9318.3

[back to top]

Average Change in the Longest Diameter of the Breast MRI Target Lesion

One of the primary outcomes of this study was to measure the impact of weekly chloroquine on the amount of DCIS seen on MRI.The tumor response was evaluated by RECIST criteria. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR The longest diameter of the target lesion or primary area of non-mass enhancement was measured by digital calipers. For one patient, the longest diameter was difficult to measure due to the presence of a significant post biopsy resolving hematoma at the biopsy site. Further correlation was made based on the extent of the pre-treatment microcalcifications and post treatment areas of non-mass enhancement. (NCT01023477)
Timeframe: Immediately preceding study drug treatment and again after treatment prior to surgery. The total time interval was up to 8 weeks

Interventionpercentage length change (Mean)
Chloroquine Standard Dose (500mg/Week)6
Chloroquine Low Dose (250mg/Week)43

[back to top]

Effect of Chloroquine on Proliferating Cell Nuclear Antigen (PCNA) Proliferation Index

We evaluated the effect of therapy on cellular proliferation as measured by the change in proliferating cell nuclear antigen (PCNA) proliferation index. PCNA , which is elevated during the G1/S phase of the cell cycle, may be used as a marker of cellular proliferation. The PCNA proliferation index was measured as the number of PCNA positive stained cells in the DCIS lesion/ total number of cells in the lesion. The change in the PCNA index is equal to the mean PCNA proliferation index pre-treatment minus the mean PCNA proliferation index post-treatment. (NCT01023477)
Timeframe: At the time of breast biopsy and again at time of surgery.

InterventionChange in PCNA proliferation index (Mean)
Chloroquine Standard Dose (500mg/Week)50.4
Chloroquine Low Dose (250mg/Week)56.71

[back to top]

Fever Clearance Time (FCT)

Measure of body temperature every 12 hours through day 7 was used to determine the time (to nearest 12 hours) from initiation of treatment until subjects temperature decreased to 37.2C and remained at or below that level for a minimum of 24 hours. (NCT01290601)
Timeframe: through day 7

InterventionHours (Mean)
Cohort 1 Tafenoquine41.5
Cohort 1-Chloroquine24.7

[back to top]

Adequate Clinical Response (ACR) of Tafenoquine: 28 Day Cure Rate

A subject will be considered a success (cure) if they have an Adequate Clinical Response (ACR). Tafenoquine was efficacious if the lower bound of the two-sided 90% confidence interval for the day 28 cure rate was not less than 85% (NCT01290601)
Timeframe: 28 Days

,
InterventionParticipants (Count of Participants)
Adequate Clinical Response (ACR)Early Treatment FailureLate Treatment Failure
Cohort 1 Tafenoquine4051
Cohort 1-Chloroquine2202

[back to top]

Number of Subjects Without Relapse of P. Vivax

"Number of subjects without relapse of P. vivax at 2, 3 and 4 months~- Blood smears were obtained at Days 28, 60, 90 and 120 to confirm the continued absence of P. vivax parasitemia" (NCT01290601)
Timeframe: Day 28, Months 2, 3 and 4

,
Interventionparticipants (Number)
Cleared at Day 28Relapsed by Day 60Relapsed by Day 90Relapsed by Day 120Without Relapse by Day 120Unevaluable by Day 120
Cohort 1 Tafenoquine40000355
Cohort 1-Chloroquine22011192

[back to top]

Parasite and Gametocyte Clearance Time (PCT and GCT)

Serial blood smears to detect the presence of P. vivax parasites and gametocytes, conducted every 12 hours up to and including day 7, until blood smear became negative were utilized to determine the time to clearance. PCT and GCT were considered cleared if 2 consecutive blood smears were negative. (NCT01290601)
Timeframe: up to day 7 after baseline smear

,
InterventionHours (Mean)
Parasite Clearance TimeGametocyte Clearance Time
Cohort 1 Tafenoquine83.448.3
Cohort 1-Chloroquine40.022.7

[back to top]

Safety and Tolerability of Tafenoquine as Defined by Most Common Adverse Events (AEs)

To evaluate the safety and tolerability of the tafenoquine dosing regimens as defined by the most common AE's overall, occurring in >10% of subjects in either treatment group (NCT01290601)
Timeframe: 90 Days

,
InterventionAEs (Number)
Blood methemoglobin presentHeadacheKeratopathyUpper respiratory tract infectionDizzinessRetinopathyEosinophiliaAbdominal painNauseaThrombocytopeniaEosinophil count increasedPyrexia
Cohort 1 Tafenoquine46141413129866655
Cohort 1-Chloroquine2240531753033

[back to top]

Number of Participants With Hematology Laboratory Data Outside the Reference Range

Blood samples were collected for the evaluation of hematology parameters including eosinophils, leukocytes, lymphocytes, neutrophils, platelets, reticulocytes and methemoglobin. The number of participants with hematology laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120

,,
InterventionParticipants (Number)
Blood eosinophils, HighBlood leukocytes, LowBlood lymphocytes, LowBlood lymphocytes, HighBlood neutrophils, LowBlood platelets, LowBlood reticulocytes, HighMethemoglobin, High
CQ Only180723214724
PQ + CQ2820137158511
TQ + CQ3834325351415

[back to top]

Number of Participants Who Received Blood Transfusion

The number of participants who received blood transfusion as a result of hemoglobin decline has been summarized. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
CQ Only0
TQ + CQ0
PQ + CQ0

[back to top]

Number of Participants With Acute Renal Failure

There were no participants with acute renal failure in the study. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
CQ Only0
TQ + CQ0
PQ + CQ0

[back to top]

Number of Participants With Recurrence-free Efficacy at 4 Months Post Dose

A participant (par) was considered to have demonstrated recurrence-free efficacy at 4 months if: a) Par had non-zero P vivax asexual parasite count at Baseline. b) Par showed initial clearance of P vivax parasitemia. c) Par had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 130 following initial parasite clearance. d) Par did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment after Study Day 109 (up to and including Study Day 130). e) Par is parasite-free at 4 months defined as a negative asexual P vivax parasite count at the first parasite assessment performed after Study Day 109 (up to and including Study Day 130). Par were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites or did not have a 4 month assessment. The number of par with recurrence-free efficacy at 4 months has been summarized. (NCT01376167)
Timeframe: 4 months post dose

InterventionParticipants (Number)
CQ Only47
TQ + CQ177
PQ + CQ90

[back to top]

Number of Participants With Recurrence-free Efficacy at 6 Months Post Dose

A participant was considered to have demonstrated recurrence-free efficacy at 6 months if: a) Participant had non-zero P vivax asexual parasite count at Baseline. b) Participant showed initial clearance of P vivax parasitemia defined as two negative asexual P vivax parasite counts, with at least 6 hours between the counts, and no positive counts in the interval. c) Participant had no positive asexual P vivax parasite count at any assessment prior to or on Study Day 201 following initial parasite clearance. d) Participant did not take a concomitant medication with anti-malarial activity at any point between Study Day 1 and their last parasite assessment. e) Participant is parasite-free at 6 months. Participants were censored if they did not have P.vivax at Baseline, or took a drug with anti-malarial action despite not having malaria parasites, or did not have a 6 month assessment. The number of participants with recurrence-free efficacy at 6 months has been summarized. (NCT01376167)
Timeframe: 6 months post dose

InterventionParticipants (Number)
CQ Only35
TQ + CQ155
PQ + CQ83

[back to top]

Oral Clearance (CL/F) of TQ

Apparent population oral clearance of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60

InterventionLiters per hour (Median)
Participants in TQ Only Arms2.96

[back to top]

Time to Fever Clearance

Fever clearance time was defined as time from first dose of treatment to the time when body temperature falls to normal within Study Days 1-4 and remains normal for at least 48 hours up to the Day 8 visit. Fever clearance was considered to have been achieved once an initial temperature of more than 37.40 degree Celsius is reduced to a value less than or equal to 37.40 degree Celsius and in the absence of value more than 37.40 degree Celsius in the following 48 hours up to the Day 8 visit. The time taken to achieve fever clearance was analyzed using Kaplan Meier Methodology. The median fever clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180

InterventionHours (Median)
CQ Only7
TQ + CQ7
PQ + CQ8

[back to top]

Time to Parasite Clearance

Parasite clearance time was defined as time needed to clear asexual parasite from the blood that is, parasite numbers falling below the limit of detection in the thick blood smear and remaining undetectable after 6 to 12 hours. The time taken to achieve parasite clearance was analyzed using Kaplan Meier Methodology. The median parasite clearance time along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180

InterventionHours (Median)
CQ Only43
TQ + CQ45
PQ + CQ42

[back to top]

Time to Recurrence of P Vivax Malaria

Recurrence was defined as the first confirmed presence of P vivax asexual stage parasites after clearance of initial parasitemia following CQ treatment. Time to recurrence was defined as the time (in days) from initial parasite clearance to recurrence. The time to recurrence was analyzed by the Kaplan-Meier method. NA indicates data was not available due to insufficient number of participants with events during the follow up period in the study. The median number of days to recurrence along with 95% confidence interval has been presented for each treatment group. (NCT01376167)
Timeframe: Up to Day 180

InterventionDays (Median)
CQ Only86
TQ + CQNA
PQ + CQNA

[back to top]

Volume of Distribution (Vc/F) of TQ

Apparent population central volume of distribution of TQ (NCT01376167)
Timeframe: Day 2, Day 8, Day 15, Day 29 and Day 60

InterventionLiters (Median)
Participants in TQ Only Arms915

[back to top]

Change From Baseline in Percent Methemoglobin

Methemoglobin assessment was made with the aid of a non-invasive signal extraction pulse CO-Oximeter handheld machine (Masimo). The change from Baseline in percent methemoglobin by treatment, time and sex has been summarized. The last assessment performed prior to the first dose of study medication (CQ or randomized treatment) was considered as Baseline. Change from Baseline was calculated as the post baseline assessment minus the Baseline assessment for percent methemoglobin. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 120

,,
InterventionPercent Methemoglobin (Mean)
Day 2, MaleDay 2, FemaleDay 3, MaleDay 3, FemaleDay 5, MaleDay 5, FemaleDay 8, MaleDay 8, FemaleDay 11, MaleDay 11, FemaleDay 15, MaleDay 15, FemaleDay 22, MaleDay 22, FemaleDay 29, MaleDay 29, FemaleDay 60, MaleDay 60, FemaleDay 120, MaleDay 120, Female
CQ Only-0.18-0.22-0.15-0.20-0.28-0.20-0.12-0.16-0.07-0.130.12-0.080.07-0.05-0.10-0.180.440.190.200.10
PQ + CQ-0.10-0.01-0.020.111.280.903.012.583.613.413.513.631.961.860.580.490.200.160.370.37
TQ + CQ-0.030.10-0.010.260.421.370.982.041.172.130.941.670.540.930.230.24-0.100.030.07-0.03

[back to top]

Cost Associated With Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionUS Dollars (USD) (Mean)
Brazil (Drug shop for care)Brazil (Enrollment clinic for care)Brazil (other location for care)Peru (Drug shop for care)Peru (Enrollment clinic for care)Peru (Attended another clinic)Peru (Other location for care)Thailand (Drug shop for care)Thailand (Enrollment clinic for care)Thailand (In-hospital care)
First Malaria Recurrence4.766.174.231.478.782.710.724.6019.156.13

[back to top]

Cost Associated With Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the total costs spent on treatment, transport, medication and tests. The cost was summarized according to the place at which the participant went to for care (drug shop, trial clinic, other clinic, hospital (inpatient/outpatient), traditional healer, other). The reported costs by type and by site has been summarized. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionUS Dollars (USD) (Mean)
Brazil (Enrollment clinic for care)Peru (Enrollment clinic for care)Peru (Attended another clinic)Peru (Other location for care)
First Malaria Recurrence Follow-up6.158.543.941.30

[back to top]

Cost Incurred With Purchase of Medications Associated With Recurrence Episode of Malaria

"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180

InterventionUSD (Mean)
Peru, n=23, 3
First Malaria Recurrence Follow-up0.32

[back to top]

Cost Incurred With Purchase of Medications Associated With Recurrence Episode of Malaria

"Health outcomes were evaluated based on the cost of medications purchased. The reported total medication cost for paracetamol associated with recurrence episode of P vivax malaria has been reported by site. Where costs have not been reported at a visit, the number of participants analyzed is given as 0. Medications recorded as Other and medications without costs are excluded from the analysis. Only those participants with data available at the specified data points were analyzed." (NCT01376167)
Timeframe: Up to Day 180

InterventionUSD (Mean)
Peru, n=23, 3Brazil, n=6, 0
First Malaria Recurrence0.491.70

[back to top]

Incidence of Visual Field Abnormalities Based on Best Corrected Visual Acuity Test Scores

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionlogMAR scores (Mean)
Baseline; right eyeBaseline; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eye
CQ Only0.0410.0480.0390.0320.0440.041

[back to top]

Incidence of Visual Field Abnormalities Based on Best Corrected Visual Acuity Test Scores

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Best corrected visual acuity was assessed individually for each eye. Scores were recorded as a ratio. The values were used to derive a logMAR score for statistical analysis where logMAR=-1x log10 (ratio score). The mean and standard deviation of logMAR score for each treatment group has been summarized. High scores were associated with worse vision, and low scores with better vision. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

,
InterventionlogMAR scores (Mean)
Baseline; right eyeBaseline; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eyeDay 180; right eyeDay 180; left eye
PQ + CQ0.0290.0480.0210.0450.0160.0410.0000.000
TQ + CQ0.0460.0390.0490.0320.0380.0280.0330.033

[back to top]

Number of Participants With Action Taken to Treat Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Brazil, NothingBrazil, Drug shopBrazil, Trial clinicBrazil, OtherCambodia, NothingEthiopia, NothingEthiopia, Another clinicEthiopia, OtherEthiopia, Trial clinicPeru, NothingPeru, Drug shopPeru, Trial clinicPeru, Another clinicPeru, OtherThailand, NothingThailand, Drug shopThailand, Trial clinicThailand, In hospital
First Malaria Recurrence Follow-up507601413001006354116000

[back to top]

Number of Participants With Action Taken to Treat Recurrence Episode of P Vivax Malaria

Health outcomes were evaluated based on the actions taken by the participants to treat recurrence episode of P vivax malaria. The reported action taken by site is summarized. Where no action by site have been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Brazil, NothingBrazil, Drug shopBrazil, Trial clinicBrazil, OtherCambodia, NothingEthiopia, NothingEthiopia, Another clinicEthiopia, OtherEthiopia, Trial clinicPeru, NothingPeru, Drug shopPeru, Trial clinicPeru, Another clinicPeru, OtherPhilippines, NothingThailand, NothingThailand, Drug shopThailand, Trial clinicThailand, In hospital
First Malaria Recurrence212622131211018611015111131

[back to top]

Number of Participants With Clinical Chemistry Laboratory Data Outside the Reference Range

Blood samples were collected for the evaluation of clinical chemistry parameters including Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk. Phos), Aspartate Aminotransferase (AST), bilirubin, creatine kinase, creatinine, glomerular filtration rate (GFR), indirect bilirubin and urea. The number of participants with clinical chemistry laboratory data outside the extended normal range (F3) was presented. The upper and lower limits for F3 range were defined by multiplying the normal range limits by different factors. High and low indicated that the participants had values flagged as high and low respectively for the particular parameter any time on-treatment. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 120

,,
InterventionParticipants (Number)
ALT, HighAlk Phos, HighAST, HighBilirubin, HighCreatine kinase, HighCreatinine, HighGFR, LowIndirect bilirubinUrea, High
CQ Only1135188001142
PQ + CQ51212800846
TQ + CQ1017235112285

[back to top]

Number of Participants With Gastrointestinal Disorders

Gastrointestinal tolerability was analyzed by the number of par experiencing gastrointestinal disorders such as abdominal pain, heartburn, diarrhea, constipation, nausea, and vomiting. The number of participants with gastrointestinal disorders for each treatment group has been summarized. (NCT01376167)
Timeframe: Up to Day 180

,,
InterventionParticipants (Number)
NauseaVomitingAbdominal pain upperDiarrhoeaAbdominal painDyspepsia
CQ Only12913655
PQ + CQ9117562
TQ + CQ2122111586

[back to top]

Number of Participants With Hemoglobin Decline From Baseline Over First 29 Days

Glucose-6-phosphate dehydrogenase deficiency (G6PD) deficiency is known to be a risk factor for hemolysis in participants treated with 8-aminoquinolines. Blood samples were collected for the evaluation of hemoglobin levels. Hemoglobin decreases of >=30% or >3 grams/deciliter (g/dL) from Baseline; or, an overall drop in hemoglobin below 6.0 g/dL in the first 15 days of the study were considered as protocol defined serious adverse events (SAEs). Number of participants with maximum hemoglobin decline from Baseline over first 29 days of study has been summarized. Safety Population consisted of all randomized participants who received at least one dose of study medication. (NCT01376167)
Timeframe: Baseline and up to Day 29

,,
InterventionParticipants (Number)
<=20 grams/liter (g/L)>20g/L to <=30 g/L>30 g/L or >=30%
CQ Only120112
PQ + CQ114123
TQ + CQ2143114

[back to top]

Number of Participants With Keratopathy

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionParticipants (Number)
Baseline; right eyeBaseline; left eyeDay 1; right eyeDay 1; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eyeAny time post Baseline; right eyeAny time post Baseline; left eye
CQ Only0000000000

[back to top]

Number of Participants With Keratopathy

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. The number of participants displaying keratopathy in each eye was summarized for each visit. The number of participants with new keratopathy at any time post Baseline was also reported. Ophthalmic Safety Population comprised of all participants in the Safety Population who have results from any eye assessments. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

,
InterventionParticipants (Number)
Baseline; right eyeBaseline; left eyeDay 1; right eyeDay 1; left eyeDay 29; right eyeDay 29; left eyeDay 90; right eyeDay 90; left eyeDay 180; right eyeDay 180; left eyeAny time post Baseline; right eyeAny time post Baseline; left eye
PQ + CQ000000000000
TQ + CQ000000100010

[back to top]

Number of Participants With Retinal Changes From Baseline

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180

,
InterventionParticipants (Number)
Day 29, Definite change, right eyeDay 29, Ques change, right eyeDay 29, Definite change, left eyeDay 29, Ques change, left eyeDay 90, Definite change, right eyeDay 90, Ques change, right eyeDay 90, Definite change, left eyeDay 90, Ques change, left eyeDay 180, Definite change, right eyeDay 180, Ques change, right eyeDay 180, Definite change, left eyeDay 180, Ques change, left eye
CQ Only101010100000
TQ + CQ000010110000

[back to top]

Number of Participants With Retinal Changes From Baseline

Ophthalmic assessments were carried out at pre-qualified sites (Manaus) prior to randomization and at Days 29 and 90 and at withdrawal. Assessments were carried out at Day 180 if the Day 90 assessments showed abnormalities. The last assessment performed on the day of randomization or earlier was considered Baseline. Change from Baseline was calculated as the post Baseline assessment minus the Baseline assessment. The number of participants with definite retinal change and questionable (ques) retinal change from Baseline was presented. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Baseline and up to Day 180

InterventionParticipants (Number)
Day 29, Definite change, right eyeDay 29, Ques change, right eyeDay 29, Definite change, left eyeDay 29, Ques change, left eyeDay 90, Definite change, right eyeDay 90, Ques change, right eyeDay 90, Definite change, left eyeDay 90, Ques change, left eye
PQ + CQ00001102

[back to top]

Number of Participants With TEAEs and Serious TEAEs

An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/ birth defect, other situations and is associated with possible drug induced liver injury with hyperbilirubinemia. TEAEs is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with TEAEs and serious TEAEs have been presented. (NCT01376167)
Timeframe: Up to Day 180

,,
InterventionParticipants (Number)
TEAEsSerious TEAEs
CQ Only866
PQ + CQ764
TQ + CQ16421

[back to top]

Number of Participants With TEAEs by Maximum Intensity

An AE is defined as any untoward medical occurrence in a participant under clinical investigation, temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AEs with an onset date and time on or after that of the start of first dose of study medication (including CQ). Number of participants with AEs based on severity has been presented. (NCT01376167)
Timeframe: Up to Day 180

,,
InterventionParticipants (Number)
Mild or Grade 1Moderate or Grade 2Severe or Grade 3Grade 4Grade 5
CQ Only3052310
PQ + CQ3837100
TQ + CQ7089201

[back to top] [back to top]

Time Lost by Participants or Care Givers From Normal Occupation

Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionDays (Number)
Brazil, HouseworkBrazil, FarmingBrazil, paid employmentBrazil, OtherCambodia, FarmingEthiopia, HouseworkEthiopia, FarmingEthiopia, StudentEthiopia, Paid employmentEthiopia, OtherPeru, HouseworkPeru, FarmingPeru, StudentPeru, Paid employmentPeru, OtherThailand, paid employmentThailand, Other
First Malaria Recurrence Follow-up00052433047292868.53200

[back to top]

Time Lost by Participants or Care Givers From Normal Occupation

Health outcomes were evaluated based on total time lost by participants or care givers due to an episode of malaria. The reported time lost due to recurrence episode of P vivax malaria has been summarized by category and by site. Where categories by site have not been reported at a visit, the number of participants analyzed is given as 0. Only those participants with data available at the specified data points were analyzed. (NCT01376167)
Timeframe: Up to Day 180

InterventionDays (Number)
Brazil, HouseworkBrazil, FarmingBrazil, paid employmentBrazil, OtherCambodia, FarmingEthiopia, HouseworkEthiopia, FarmingEthiopia, StudentEthiopia, Paid employmentEthiopia, OtherPeru, HouseworkPeru, FarmingPeru, StudentPeru, Paid employmentPeru, OtherPhilippines, FarmingThailand, paid employmentThailand, Other
First Malaria Recurrence18831742.5321241916260201

[back to top]

Cumulative Excess Systemic Steroid Dose From Time of Clinically Significant Disease Reactivation to Return to Pre-Flare Dose or End of Trial Participation

"For each participant who experienced disease reactivation, excess systemic steroid dose was summed from the time of clinically significant disease reactivation until the dose returns to pre-flare levels or the end of study participation, whichever occurred first. Excess systemic steroid dose was defined as the total dose given for the flare minus (-) a participant's pre-flare steroid dose. Participants who do not have an increase in their steroid use due to the flare had their excess dose set to zero. Steroids include medications that code to a medication class which includes the terms glucocorticoid or corticosteroid. Systemic steroids will include any of these steroids that are taken by mouth (PO), intravenous (IV), or intramuscular (IM)." (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionSteroid dose (mg) (Mean)
MMF Maintenance812.8
MMF Withdrawal1750.7

[back to top]

The Addition of Aggressive Adjunctive Therapy to Mycophenolate Mofetil (MMF) or Change in MMF Therapy to Cytotoxic Drug Due to Flare by Week 60

The addition of aggressive adjunctive therapy could include intravenous (IV) immunoglobulin or rituximab at any point during the participant's study participation. A change in therapy to cytotoxic drug due to flare could include drugs such as cyclophosphamide, etc. A blinded list of study medications was reviewed to identify the addition of aggressive adjunctive therapy or cytotoxic drugs. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance0
MMF Withdrawal1

[back to top]

Time to First Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare

The time to first severe SELENA-SLEDAI flare was defined as the time from Baseline/Day 0 to the date of the first severe SELENA-SLEDAI flare. Time to severe SELENA-SLEDAI flare was defined in study weeks as: date of SELENA-SLEDAI flare minus (-) baseline date. The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes mild/moderate or severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionWeeks (Mean)
MMF Maintenance43.5
MMF Withdrawal41.5

[back to top]

Change From Baseline in the Functional Assessment of Chronic Illness Therapy (FACIT-F) Fatigue Scale (FS): Total Score

FACIT-Fatigue scale (FS) is a 13-item questionnaire completed by the patient (participant), that provides a measure of fatigue/quality of life, with a 7-day recall period. The participant scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the participant's response to the questions (with the exception of 2 negatively stated), the greater the fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as 4 minus the participant's response. The sum of all responses resulted in the FACIT-FS score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflected an improvement in the participant's health status. A decrease in the FACIT-FS score reflects worse fatigue/quality of life. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
Interventionunits on a scale (Mean)
Week 24Week 48Week 60
MMF Maintenance-2.41-3.39-3.13
MMF Withdrawal-0.81-0.850.42

[back to top]

Change From Baseline in the Lupus Quality of Life (QoL)Score

The Lupus QoL assessment is a 34 item questionnaire across 8 domains that is designed to find out how systemic lupus erythematosus (SLE) affects a participant's life over the preceding 4 weeks. Scores range from 0 (worst QoL) to 100 (best QoL). Domains include physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Change in Physical Health at Week 24Change in Physical Health at Week 48Change in Physical Health at Week 60Change in Pain at Week 24Change in Pain at Week 48Change in Pain at Week 60Change in Planning at Week 24Change in Planning at Week 48Change in Planning at Week 60Change in Intimate Relationships at Week 24Change in Intimate Relationships at Week 48Change in Intimate Relationships at Week 60Change in Burden to Others at Week 24Change in Burden to Others at Week 48Change in Burden to Others at Week 60Change in Emotional Health at Week 24Change in Emotional Health at Week 48Change in Emotional Health at Week 60Change in Body Image at Week 24Change in Body Image at Week 48Change in Body Image at Week 60Change in Fatigue at Week 24Change in Fatigue at Week 48Change in Fatigue at Week 60
MMF Maintenance-1.11-2.830.00-0.17-3.10-0.190.35-5.43-3.03-1.47-0.81-2.081.56-0.58-1.33-0.87-2.03-1.522.94-0.173.223.78-2.18-0.57
MMF Withdrawal1.040.461.561.771.601.423.90-0.180.184.29-1.102.860.18-4.43-3.550.09-1.22-0.87-1.09-0.56-4.45-1.17-1.56-1.95

[back to top]

Change From Baseline in the Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

The SF-36 is a 36-item, patient-reported survey of patient health. Higher scores indicate better outcomes while lower scores indicate more disability. The Physical Component Score is comprised of the Physical Functioning Scale, the Role-Physical Scale, the Bodily Pain Scale, and the General Health Scale. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Week 24Week 48Week 60
MMF Maintenance-0.75-1.92-1.51
MMF Withdrawal0.900.251.51

[back to top]

Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance1
MMF Withdrawal1

[back to top]

Change From Baseline in the Short Form Health Survey (SF-36) Physical Functioning (PF) Score

The SF-36 is a 36-item, patient-reported survey of patient health. Higher scores indicate better outcomes while lower scores indicate more disability. The PF score is used to assess changes in physical functioning. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Week 24Week 48Week 60
MMF Maintenance-0.33-0.49-0.19
MMF Withdrawal0.220.951.79

[back to top]

Number of Grade 3, 4, or 5 Adverse Events (AEs)

The number of Grade 3, 4, or 5 AEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

,
InterventionAdverse Events (Number)
Grade 3Grade 4Grade 5
MMF Maintenance1820
MMF Withdrawal1500

[back to top] [back to top] [back to top]

All-Cause Mortality

All-cause mortality is defined as death from any cause occurring after randomization. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance0
MMF Withdrawal0

[back to top]

Number of Grade 3, 4, or 5 Hematological Adverse Events (AEs).

The number of Grade 3, 4, or 5 hematological AEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

,
InterventionAdverse Events (Number)
Grade 3Grade 4Grade 5
MMF Maintenance300
MMF Withdrawal000

[back to top]

Cumulative Systemic Steroid Dose by Week 60

"Steroids include medications that code to a medication class which includes the terms glucocorticoid or corticosteroid. Systemic steroids will include any of these steroids that are taken by mouth (PO), intravenous (IV), or intramuscular (IM). Total cumulative systemic steroid dose, in milligrams, was summarized over the 60 week study period, or until early study termination, for each participant." (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

Interventionsteroid dose (mg) (Mean)
MMF Maintenance851
MMF Withdrawal912

[back to top] [back to top] [back to top]

Number of Malignancies Reported as Adverse Events (AEs).

The number of malignancies reported as AEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionAdverse Events (Number)
MMF Maintenance2
MMF Withdrawal3

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes mild/moderate or severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance20
MMF Withdrawal25

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance9
MMF Withdrawal12

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF<2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance11
MMF Withdrawal13

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance15
MMF Withdrawal19

[back to top]

Number of Participants Experiencing a Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Non-Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance5
MMF Withdrawal6

[back to top]

Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance4
MMF Withdrawal8

[back to top]

Number of Participants Experiencing a Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 Within the Lupus Nephritis Subgroup

The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance3
MMF Withdrawal7

[back to top]

Change From Baseline in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Disease Damage Index for Systemic Lupus Erythematosus (SLICC/DI): Total Score

The SLICC/DI measures accumulated damage that has occurred since the onset of systemic lupus erythematosus (SLE), regardless of cause, in 12 organ systems. SLE damage is defined as an irreversible change in an organ or system that has been present for at least 6 months. The SLICC/DI includes 39 areas of damage in 12 domains, where each item is rated as present or absent; if evidence of damage is present for a particular item, it is given a score of 1. Some items are scored with 2 or 3 points in the case of recurring events or end stage renal disease. The SLICC/DI total score will be computed as the sum of all scores for items indicated as present; scores can range from 0 to 45. Higher scores indicate more damage. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 24, Week 48, and Week 60

,
InterventionScores on a Scale (Mean)
Week 24Week 48Week 60
MMF Maintenance0.00.00.0
MMF Withdrawal0.00.00.0

[back to top]

Number of Participants Experiencing Any British Isles Lupus Assessment Group (BILAG) A Flare by Week 60

The BILAG assesses participants on a variety of disease activity criteria in nine body system categories (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematological). Each category is scored as an A, B, C, or D/E, where A indicates most severe disease activity and D/E indicates inactive/no disease activity. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance1
MMF Withdrawal4

[back to top]

Number of Participants Experiencing Clinically Significant Disease Reactivation by Week 60

Disease reactivation requires:1) SELENA-SLEDAI mild/moderate or severe flare,and 2) Increased immunosuppressive therapy on a sustained basis,defined by one of the following criteria:a) Sustained activity:Significant prolonged SLE flare requiring steroid increase/burst to ≥15 mg/day prednisone (or equivalent) for >4 weeks.b) Frequent relapsing/remitting:Participant flares requiring an increase/burst of steroids and is successfully tapered to <15 mg/day within 4 weeks, but this occurs on >2 occasions, or IA, IM or IV steroids on more than1 occasion.c)Clinical activity of sufficient severity to warrant resumption of/increased dose of MMF or addition of other major immunosuppressive including AZA or MTX.Regardless of steroid use, if the investigator observes disease activity of sufficient severity to warrant resumption, addition or increase in dosage of major immunosuppressant in the setting of a SELENA-SLEDAI flare, participant has met the primary endpoint.Risk difference also included (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance5
MMF Withdrawal9

[back to top]

Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF <2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance3
MMF Withdrawal6

[back to top]

Number of Participants Experiencing Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare by Week 60 in the Baseline MMF ≥ 2000 mg/Day Subgroup

"The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included.~MMF: mycophenolate mofetil" (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance1
MMF Withdrawal2

[back to top]

Number of Participants in the Lupus Nephritis Subgroup Experiencing a British Isles Lupus Assessment Group (BILAG) A Renal Flare by Week 60

The BILAG assesses participants on a variety of disease activity criteria in nine body system categories (constitutional, mucocutaneous, neuropsychiatric, musculoskeletal, cardiorespiratory, gastrointestinal, ophthalmic, renal, and hematological). Each category is scored as an A, B, C, or D/E, where A indicates most severe disease activity and D/E indicates inactive/no disease activity. An estimate of the risk difference ((i.e. risk(MMF Withdrawal) - risk(MMF Maintenance) and its corresponding 95% confidence interval (CI) were also included. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionParticipants (Count of Participants)
MMF Maintenance0
MMF Withdrawal2

[back to top]

Number of Serious Adverse Events (SAEs).

The number of SAEs. The severity of AEs was classified using the National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI-CTCAE), Version 4.0. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionSerious Adverse Events (Number)
MMF Maintenance12
MMF Withdrawal6

[back to top]

Time From Clinically Significant Disease Reactivation to Improvement in British Isles Lupus Assessment Group (BILAG) From Maximum Level During Flare

For each participant who experienced disease reactivation, time from clinically significant disease reactivation to improvement in BILAG from maximum level (at least an A or B) during the flare was calculated in study days as: date of clinically significant disease reactivation minus (-) date of BILAG improvement. If multiple body systems had a BILAG flare at the visit, then the body system with the most severe score was tracked for improvement; if multiple body systems had the same score (at least an A or B), then just one needed to show improvement. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionDays (Mean)
MMF Maintenance114.5
MMF Withdrawal40.5

[back to top]

Time From Clinically Significant Disease Reactivation to Recovery to Baseline British Isles Lupus Assessment Group (BILAG) Score or BILAG C

For each participant who experienced disease reactivation, time from clinically significant disease reactivation to recovery to baseline BILAG scores or BILAG C, whichever is worse, was calculated in study days as: date of clinically significant disease reactivation minus (-) date of BILAG recovery. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionDays (Mean)
MMF Maintenance114.5
MMF Withdrawal77.7

[back to top]

Time From Clinically Significant Disease Reactivation to Return to Pre-Flare Steroid Dose

For each participant who experienced disease reactivation, time from clinically significant disease reactivation to recovery to pre-flare steroid dose was calculated in study days as: date of clinically significant disease reactivation minus (-) date of return to pre-flare steroid dose. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionDays (Mean)
MMF MaintenanceNA
MMF Withdrawal37

[back to top]

Time to Clinically Significant Disease Reactivation

The time to clinically significant disease reactivation was defined as the time from Baseline/Day 0 to the date of the first Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) assessment that met (or went on to meet) the criteria for clinically significant disease reactivation. Time to clinically significant disease reactivation was defined in study weeks as: date of SELENA-SLEDAI assessment that met reactivation criteria minus (-) baseline date. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionWeeks (Mean)
MMF Maintenance38.0
MMF Withdrawal38.5

[back to top]

Time to First Mild/Moderate or Severe Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus-Disease Activity Index (SELENA-SLEDAI) Flare

The time to first mild/moderate or severe SELENA-SLEDAI flare was defined as the time from Baseline/Day 0 to the date of the first mild/moderate or severe SELENA-SLEDAI flare. Time to SELENA-SLEDAI flare was defined in study weeks as: date of SELENA-SLEDAI flare minus (-) baseline date. The SELENA-SLEDAI assesses systemic lupus erythematosus (SLE) disease activity and categorizes mild/moderate or severe flares based on changes in the SLEDAI score, the Physician's Global Assessment (PGA), medication use (prednisone, Nonsteroidal anti-inflammatory drugs, Plaquenil, major immunosuppressives), other disease activity criteria, and hospitalization due to SLE. (NCT01946880)
Timeframe: Baseline (Treatment Randomization) to Week 60

InterventionWeeks (Mean)
MMF Maintenance20.5
MMF Withdrawal27.5

[back to top]

Biochemical Response to Therapy

The biochemical response is defined when there is normalization of hepatic enzymes, mainly AST and ALT. (NCT02463331)
Timeframe: six months

InterventionParticipants (Count of Participants)
Chloroquine Plus Prednisone14
Azathioprine Plus Prednisone21

[back to top]

Histopathological Response to Therapy

Histopathological response is achieved when there is minimal or no inflammation in hepatic tissue, as assessed by liver biopsy. (NCT02463331)
Timeframe: liver biopsy was was performed to evaluate histopathological response after 18 months of biochemical response

InterventionParticipants (Count of Participants)
Chloroquine Plus Prednisone4
Azathioprine Plus Prednisone10

[back to top]

Geometric Mean Titer (GMT) 14 Days Post Fourth Dose Post Exposure Prophylaxis (PEP) With Purified Chick Embryo Cell Vaccine (PCECV) in Each Malaria Prophylaxis Group Compared to Control to Determine if a Fifth Dose of PEP Would Add Value

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21, and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 and 14 (dose 4). Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. Descriptive analyses were based on samples taken 14 days after dose 4, (e.g., at 6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Arms and at 4 weeks for Rabies Arm). (NCT02564471)
Timeframe: 6 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and at 4 weeks for Rabies Group

InterventionIU/ml (Geometric Mean)
Chloroquine3.45
Atovaquone and Proguanil (Malarone)7.95
Doxycycline8.51
Rabies10.26

[back to top]

GMT Over Protective Titer 28 Days Post Fourth Dose of PCECV

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3,7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. (NCT02564471)
Timeframe: Up to 8 weeks for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and up to 6 weeks for Rabies Arm

InterventionIU/ml (Geometric Mean)
Chloroquine2.3
Atovaquone and Proguanil (Malarone)4.96
Doxycycline5.18
Rabies6.87

[back to top]

GMT Over Protective Titer Prior Fourth Dose of PCECV

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. (NCT02564471)
Timeframe: 28 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 14 days for Rabies Arm

InterventionIU/ml (Geometric Mean)
Chloroquine4.15
Atovaquone and Proguanil (Malarone)6.45
Doxycycline7.04
Rabies6.98

[back to top]

GMT Over Protective Titer Prior to Third Dose of PCECV

Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups received antimalarial up to day 14 and rabies vaccinations on day 14, 17, 21 (dose 3), and 28 (dose 4). Rabies Group received the rabies vaccination on days 0, 3, 7 (dose 3) and 14 (dose 4). For Chloroquine, Malarone and Doxycycline Groups, samples were taken on days 0, 21, 28 and 56. For Rabies Group, samples were taken on days 0, 7, 14 and 42. Rabies virus-specific serum antibody neutralization assay was used to measure rabies virus antibodies, using the rapid fluorescent foci inhibition test (RFFIT). A titer of >0.5 IU/ml against rabies virus as protective. (NCT02564471)
Timeframe: 21 days for Chloroquine, Atovaquone and Proguanil (Malarone) and Doxycycline Groups and 7 days for Rabies Arm

InterventionIU/ml (Geometric Mean)
Chloroquine0.14
Atovaquone and Proguanil (Malarone)0.11
Doxycycline0.16
Rabies0.17

[back to top]

Number of Participants With P.Falciparum Blood Stage Infection

Participants with P. falciparum blood stage infection defined as detection of P. falciparum parasites by qPCR (real time NIH qPCR and sensitive retrospective Laboratory of Malaria Immunology & Vaccinology (LMIV) qPCR) following Sanaria® PfSPZ Challenge (NF54) via direct venous injection (DVI). (NCT03083847)
Timeframe: 14 days post PfSPZ Challenge injection

InterventionParticipants (Number)
Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine0
Pilot (1b): 1 Dose of 1x10^5 PfSPZ Challenge + Pyrimethamine0
Pilot (1d): 1 Dose of 2x10^5 PfSPZ Challenge + Pyrimethamine0
Main (2a): 3 Doses of 2x10^5 PfSPZ + Pyrimethamine + NF54 CHMI0
Main (2b): 3 Doses of 2x10^5 PfSPZ + Pyrimethamine + 7G8 CHMI0

[back to top]

Number of Participants With Serious Adverse Events (SAEs)

Participants who had one or more episodes of serious adverse events (SAEs). SAE is defined as a life-threatening reaction or event that results in death. (NCT03083847)
Timeframe: 7 months

Interventionparticipants (Number)
Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine0
Pilot (1b):1 Injection of 1x10^5 PfSPZ Challenge+Pyrimethamine0
Pilot (1d):1 Injection of 2x10^5 PfSPZ Challenge+Pyrimethamine0
Main (2a):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+NF540
Main (2b):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+7G80
Main (3):3 Doses of 2x10^5 PfSPZ Challenge+Chloroquine+7G82
Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine0
Pilot (5b): 1 Injection of 2x10^5 PfSPZ Challenge+Chloroquine0

[back to top]

Number of Participants Requiring Treatment With Additional Anti-malarial Medication

Incidence of a clinical malaria diagnosis occurring after PfSPZ-Cvac challenge requiring treatment with atovaquone/proguanil (Malarone). (NCT03083847)
Timeframe: 12 days post PfSPZ Challenge injection

Interventionparticipants (Number)
Main (3): 3 Doses of 2x10^5 PfSPZ + Chloroquine + 7G8 CHMI0
Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine0
Pilot (5b): 1 Dose of 2x10^5 PfSPZ Challenge + Chloroquine0

[back to top]

Number of Participants With Local and Systemic Adverse Events (AEs)

Participants who had one or more episodes of related or/and unrelated adverse events (AEs). An AE is defined as any untoward medical occurrence temporarily associated with the subject's participation in research, whether or not considered related or not. Refer to adverse event table for specific AE. (NCT03083847)
Timeframe: 7 months

Interventionparticipants (Number)
Pilot (1a):1 Injection of 5x10^4 PfSPZ Challenge+Pyrimethamine2
Pilot (1b):1 Injection of 1x10^5 PfSPZ Challenge+Pyrimethamine2
Pilot (1d):1 Injection of 2x10^5 PfSPZ Challenge+Pyrimethamine3
Main (2a):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+NF548
Main (2b):3 Doses of 2x10^5 PfSPZ Challenge+Pyrimethamine+7G89
Main (3):3 Doses of 2x10^5 PfSPZ Challenge+Chloroquine+7G810
Pilot (5a): 1 Injection of 1x10^5 PfSPZ Challenge+Chloroquine2
Pilot (5b): 1 Injection of 2x10^5 PfSPZ Challenge+Chloroquine4

[back to top]

Number of Participants With Local and Systemic Adverse Events (AEs) and Serious Adverse Events (SAEs)

Count of participants with local and systemic adverse events (AEs) and serious adverse events (SAEs) occurring after PfSPZ-CVac immunization. This outcome measure applies to main phase arms 1b, 2b, 4a, and 4b. Arms 5b and 6b were not performed as patent parasitemia with the higher dose of PfSPZ was not observed in the pilot phase (Arms 1a, 2a). (NCT03952650)
Timeframe: For the main phase: from the day of inoculation to approximately 6 months post-3rd inoculation. For the booster phase: from the time of inoculation to approximately 6 months post-booster inoculation

InterventionParticipants (Count of Participants)
1b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 5788
2b - Safety/Efficacy: Dosing Interval on Days: 1, 29, 5759
4a - Safety Comparator: Dosing Interval on Days: 1, 29, 5751
4b - Safety Comparator: Dosing Interval on Days: 1, 29, 5736

[back to top]

Number of Participants With Local and Systemic Grade 3 Adverse Events (AEs) and Serious Adverse Events (SAEs)

Count of participants with local and systemic grade 3 signs or symptoms lasting more than 48 hours despite adequate management and serious adverse events (SAEs) occurring after PfSPZ-CVac DVI. Only arm 3a was analyzed for this outcome measure, per the protocol objectives. (NCT03952650)
Timeframe: From day of inoculation to 14 days post-inoculation

InterventionParticipants (Count of Participants)
3a - Pilot/Safety: Dosing Interval on Days: 10

[back to top]

Number of Participants With Positive Sensitive Blood Smear (sBS)

Count of participants with positive sensitive blood smear (sBS) occurring after PfSPZ-CVac immunization starting on day 7 post DVI. Only pilot phase arms (Arms 1a, 2a) were analyzed for this outcome measure. Arms 5a and 6a were not performed, as no patent parasitemia was observed in either Arms 1a or 2a, per the protocol. (NCT03952650)
Timeframe: 7 -12 days post-inoculation

InterventionParticipants (Count of Participants)
1a - Pilot/Safety: Dosing Interval on Days: 10
2a - Pilot/Safety: Dosing Interval on Days: 10

[back to top]